Nothing Special   »   [go: up one dir, main page]

WO1995020045A1 - Antibodies to egf receptor and their antitumour effect - Google Patents

Antibodies to egf receptor and their antitumour effect Download PDF

Info

Publication number
WO1995020045A1
WO1995020045A1 PCT/GB1995/000118 GB9500118W WO9520045A1 WO 1995020045 A1 WO1995020045 A1 WO 1995020045A1 GB 9500118 W GB9500118 W GB 9500118W WO 9520045 A1 WO9520045 A1 WO 9520045A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
antibody
cells
icr62
egfr
Prior art date
Application number
PCT/GB1995/000118
Other languages
French (fr)
Inventor
Christopher Dean
Helmout Modjtahedi
Original Assignee
The Institute Of Cancer Research: Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Institute Of Cancer Research: Royal Cancer Hospital filed Critical The Institute Of Cancer Research: Royal Cancer Hospital
Priority to EP95906400A priority Critical patent/EP0737251A1/en
Priority to AU14601/95A priority patent/AU691865B2/en
Priority to JP7519421A priority patent/JPH09510605A/en
Publication of WO1995020045A1 publication Critical patent/WO1995020045A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Definitions

  • This invention relates to the development of agents and methods for treating tumour cells. More particularly, it is concerned with antibodies against the epidermal growth factor receptor (EGFR) , which have been found to exhibit an antitu our effect.
  • EGFR epidermal growth factor receptor
  • EGFR epidermal growth factor receptor
  • This receptor is a 170 D transmembrane glycoprotein with tyrosine kinase activity which transmits the mitogenic action of the EGF family of growth factors including EGF, TGF ⁇ and amphiregulin.
  • EGF epidermal growth factor receptor
  • TGF ⁇ TGF ⁇
  • amphiregulin The binding of these ligands to the external domain of the EGF receptor initiates a number of early and delayed responses in the target cells leading ultimately to DNA synthesis and cell division.
  • Over-expression of the EGFR has been reported in a number of human malignancies including cancer of the breast, brain, bladder, head and neck, pancreas and lung (1,9-12) .
  • ICR64 directed against epitope D
  • ICR16 IgG2a
  • ICR62 IgG2b
  • the present invention provides antibodies to EGF receptor, and fragments thereof, for therapeutic use. Included in this aspect of the invention are those antibodies identified herein, and their functional equivalents, mutants and derivatives.
  • the antibodies may be murine (rat or mouse) , but preferably have framework regions and/or constant regions based on or derived from human antibodies.
  • the antibodies may be complete immunoglobulin molecules, but they may be Ig fragments, for example monovalent or divalent Ig entities such as Fab fragments, single chain Fv molecules etc.
  • the present invention discloses the use of antibodies to the EGFR, or fragments thereof, in the preparation of a medicament for inducing terminal differentiation in tumour cells, especially those which are characterised by over-expressing EGFR.
  • the present invention provides DNA encoding the above antibodies, expression vectors comprising that DNA and host cells transformed with the expression vectors.
  • the present invention provides pharmaceutical compositions comprising one or more of the above antibodies, for example selected from antibodies ICR16, ICR62 and ICR64.
  • the amounts of the antibodies used in the compositions can be determined by the skilled person, and will be typically in the range 1 to 300mg.
  • the above antibodies or fragements can be conjugated to a label, toxin or drug.
  • the antibodies could be used to target an active agent administered in a precursor form to cells, for conversion to the active form by an activating agent produced in, or targeted to, the cells to be treated. This type of approach is sometimes known as ADEPT (see for example, EP-A-415731 and WO 90/07936) .
  • peptide or mimetic molecules which mimic the antibody binding to EGFR and likewise induce terminal differentiation of tumour cells.
  • the present invention also includes the use of the above antibodies in the design or synthesis of these mimetics.
  • EGF receptor antibodies are primarily of interest in the treatment of tumour cells, they may also find applications in the treatment of other disorders, eg arthritis, psoriasis, atherosclerosis, S E, inflammation or other proliferative disorders.
  • the antibodies described above can altered in a variety of ways using recombinant DNA technology coupled with advances in the field of monoclonal antibody and protein engineering. This has enabled access to a large selection of antibodies and antibody fragments with different properties and structures to natural antibodies.
  • Monoclonal antibodies can be subjected to the techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs) , of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP-A-184187, GB 2188638A or EP-A-239400.
  • a hybridoma producing a monoclonal antibody may be subject to genetic mutation or other changes, which may or may not alter the binding specificity of antibodies produced.
  • an antibody specific for a protein may be obtained from a recombinantly produced library of expressed immunoglobulin variable domains, eg using lambda bacteriophage or filamentous bacteriophage which display functional immunoglobulin binding domains on their surfaces; for instance see WO92/01047.
  • the library may be naive, that is constructed from sequences obtained from an organism which has not been immunised with the target, or may be one constructed using sequences obtained from an organism which has been exposed to the antigen of interest
  • Antibodies may be modified in a number of ways. Indeed the term “antibody” should be construed as covering any specific binding substance having an binding domain with the required specificity. Thus this term covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, including any polypeptide comprising an immunoglobulin binding domain, whether natural or synthetic. Chimaeric molecules comprising an immunoglobulin binding domain, or equivalent, fused to another polypeptide are therefore included. Cloning and expression of chimaeric antibodies are described in EP-A- 0120694 and EP-A-0125023.
  • binding fragments are (i) the Fab fragment consisting of VL, VH, CL and CHI domains; (ii) the Fd fragment consisting of the VH and CHI domains; (iii) the Fv fragment consisting of the VL and VH domains of a single antibody; (iv) the dAb fragment (Ward, E.S. et al.
  • Diabodies are multimers of polypeptides, each polypeptide comprising a first domain comprising a binding region of an immunoglobulin light chain and a second domain comprising a binding region of an immunoglobulin heavy chain, the two domains being linked (eg by a peptide linker) but unable to associate with each other to form an antigen binding site: antigen binding sites are formed by the association of the first domain of one polypeptide within the multimer with the second domain of another polypeptide within the multimer (WO94/13804) .
  • bispecific antibodies may be conventional bispecific antibodies, which can be manufactured in a variety of ways (Holliger, P. and Winter G. Current Opinion Biotechnol.
  • Diabodies and scFv can be constructed without an Fc region, using only variable domains, potentially reducing the effects of anti-idiotypic reaction.
  • Other forms of bispecific antibodies include the single chain "Janusins" described in Traunecker et al, Embo Journal, 10, 3655-3659, (1991) .
  • Bispecific diabodies, as opposed to bispecific whole antibodies, are also particularly useful because they can be readily constructed and expressed in E. coli .
  • phage display WO94/13804
  • one arm of the diabody is to be kept constant, for instance, with a specificity directed against antigen X, then a library can be made where the other arm is varied and an antibody of appropriate specificity selected.
  • bispecific antibodies incorporating a specificity for the T-cell co-receptor CD3 have been shown to inhibit tumour growth (Titus, J. A. et al. , J. Immunol. 138, 4018-4022 (1987)) and to cure lymphoma (Brissinck J. et al, J. Immunol. 174, 4019-4026 (1991)).
  • humanise non-human (eg murine) antibodies to provide antibodies having the antigen binding properties of the non-human antibody, while minimising the immunogenic response of the antibodies, eg when they are used in human therapy.
  • humanised antibodies comprise framework regions derived from human immunoglobulins
  • acceptor antibody in which residues from one or more complementary determining regions (CDR's) are replaced by residues from CDR's of a non-human species (donor antibody) such as mouse, rat or rabbit antibody having the desired properties, eg specifici .y, affinity or capacity.
  • donor antibody such as mouse, rat or rabbit antibody having the desired properties, eg specifici .y, affinity or capacity.
  • Some of the framework residues of the human antibody may also be replaced by corresponding non-human residues, or by residues not present in either donor or acceptor antibodies.
  • Figures 1 and 2 show flow cytometric analysis of DNA in nuclei obtained from HN5 cells following four days incubation in vitro in DMEM-2%FCS alone or in DMEM-2%FP" containing anti-EGFR mAbs (156nM) or EGF (lOnM) .
  • Fi_ shows DNA histograms;
  • Fig 2 shows the percentage of cells in each phase.
  • Figures 3 and 4 show the influence of antibodies to the EGFR or their Fab fragments on the binding of 125 I-EGF (Fig 3) or 125 I-TGF ⁇ (Fig 4) to the human bladder carcinoma cell line EJ.
  • Figures 5 and 6 show Scatchard plots of 12S I-EGF binding to EJ cells in the absence or presence of monovalent and divalent mAbs ICR9 (Fig 5) and ICR62 (Fig 6) .
  • Figures 7-9 show the effect of treatment with antibodies to the EGFR or their Fab fragments on the growth in vitro of HN6 cells (Figs 7) , other head and neck carcinoma cell lines overexpres ⁇ ing the EGF receptor (Fig 8) , and the TGF ⁇ induced proliferation of quiescent human foreskin fibroblasts (Fig 9) .
  • Figure 10 shows titration curves showing the inhibition of binding of 1251-EGF to EJ cells by serum taken at the times indicated.
  • A patient 8 (20mg) ;
  • B patient 10 (40mg) ; or
  • C patient 13 (lOOmg) .
  • the starting concentration of the ICR62 standard was lOug/ml.
  • Figure 11 shows the development of human anti-rat antibodies in the serum of patient number 9 following injection of 20mg ICR62 shown by binding to intact ICR62 (A) , Fab ICR62 (B) and scFv ICR62 (C) .
  • Figure 12 the development of human anti-rat antibodies in the serum of patient number 11 following injection of 40mg of ICR62 shown by binding to intact ICR62 (A) , Fab ICR62 (B) but not scFv ICR62 (C) .
  • sequence listings show the DNA and deduced amino acid sequences of the variable regions of the heavy and light chains of ICR62 and ICR64, with the CDRs indicated in square brackets.
  • the head and neck carcinoma cell line LICR-LON-HN5 and the breast carcinoma cell line MDA-MB 468 were cultured routinely in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal calf serum (FCS) and the antibiotics penicillin, streptomycin and neomycin.
  • DMEM Dulbecco's modified Eagle's medium
  • FCS foetal calf serum
  • concentration of FCS in medium was reduced to 2% to minimize the effects of any growth factors present.
  • Isotype matched control antibodies included ALN/ll/53 (IgG2a) and 11/160 (IgG2b) which are directed against a specific antigen on the rat sarcoma HSN (27) , or RCI/4/74 (IgGl) an antibody directed against an idiotopic determinant on ICR16 (unpublished data) .
  • Monoclonal antibody to cytokeratin 10 (R SE-60) was obtained from EuroPath Ltd, Cornwall.
  • Mouse monoclonal antibody to involucrin (28) was a gift from Dr Fiona Watt (Imperial Cancer Research Fund, London) .
  • mice bearing human tumour xenografts Treatment of mice bearing human tumour xenografts with antibodies to the EGFR.
  • Xenografts of human tumours were established in athymic (nu/nu) mice and treated with antibodies as described previously (29,39) . Briefly, the protocols used were as follows.
  • HN5 tumour xenografts Since treatment of athymic mice with antibody initiated at the time of tumour inoculation results in complete and permanent regression of these tumours (39) , HN5 tumour xenografts were set up as described above but the commencement of treatment with antibodies to the EGFR was delayed until the tumours had reached a mean diameter of about 0.5cm. In this experiment groups of four to five mice were treated with antibodies ICR61 or ICR64, or with combinations of ICR61 plus ICR62 or ICR64 plus ICR62; pairs which do not compete for binding to the EGFR. In each case a second group of mice was treated with control antibodies or saline.
  • Treatment with antibodies was for five consecutive days and thereafter three times weekly until the day indicated in each experiment (total dose 2.2mg/mouse) . Animals were observed for up to 100 days or killed when the tumours reached a mean diameter of 0.8-1.0cm.
  • tumours were excised and samples were fixed in Methacarn and then embedded in paraffin. Four micron sections were cut and stained with haematoxylin and eosin (H & E) .
  • DAB [lOOmg DAB in 100ml of 0.1 M Tris buffer pH7.2, 100ml H 2 0, 66 ⁇ l H 2 0 2 ] .
  • the sections were washed twice in DDW, counterstained in Mayer's haemalum for 1 minute, dehydrated by passing through graded alcohols then mounted in DPX.
  • staining of the frozen sections was performed as above but without incubation in the primary antibody in order to visualize the presence of any remaining therapeutic mAb.
  • HN5 cells (7.5 x 10 s ) were seeded into 25cm 2 Nunc flasks (Gibco Europe Ltd, Scotland) containing 15ml DMEM plus 2%
  • FCS Monoclonal antibody (25 ⁇ g/ml) , EGF (lOnM) or the equivalent amount of medium only was then added and the cultures were incubated for four days at 37°C.
  • Flow cytometric analysis of the nuclei prepared from these cells was performed essentially as described by Ormerod et al (30) . Briefly, a suspension of single cells from each flask was prepared in 200 ⁇ l of PBS and this was followed by the vigorous addition of 2ml ice cold 70% ethanol-30% PBS. The cells were incubated for at least 30 minutes at 4°C, harvested by centrifugation and resuspended in 700 ⁇ l PBS.
  • RNAse lmg/ml, Sigma
  • propidium iodide lOO ⁇ g/ml, Sigma
  • 5xl0 4 HN5 cells were plated onto glass cover slips in 24 well plates containing 1ml DMEM plus 2%FCS. Following overnight incubation at 37°C, specific or control antibodies (25 ⁇ g/ml) or medium alone were added to the cultures and the cells were incubated for a further three to four days at 37°C. After two washes with PBS, the cells were fixed for 5 minutes in ice-cold methanol then washed by incubation in PBS for 30 minutes. Mouse anti-cytokeratin 10 or anti-involucrin mAb diluted in PBS-0.5% BSA was added and the coverslips were incubated at 4°C for 1 hour.
  • HN5 tumour xenografts following treatment with one, or a combination of two anti-EGFR mAbs that bind to two distinct epitopes on the external domain of the human EGF receptor.
  • ICR62 plus ICR64 total dose 2.2mg/mouse
  • HN5 tumour xenografts were treated from day 5-24 with antibody ICR61, 2/8 tumours had disappeared completely when the experiment was terminated on day 75 (29) .
  • Examination of the nodules remaining also showed that few if any viable cells were present and the lesions were similar in appearance to those described above.
  • An H & E stained section of an HN5 nodule remaining after treatment from day 7-24 with a combination of ICR61 plus ICR62 (total dose 2.2mg/mouse) showed that zones of keratinisation and apparent squamous differentiation were present. Indeed, keratinized areas could be found in all of the tumour lesions remaining in mice that had undergone treatment with the specific antibodies used either alone or in combination.
  • tumours were excised, cryosections were prepared and stained with peroxidase conjugated F(ab') 2 rabbit anti-rat IgG.
  • the uniform staining of the tumour cell membranes with the second antibody shows that all of the tumour cells were coated with specific rat antibody at this time.
  • the total area of tumour remaining was smaller in the mice treated with ICR62 (mean tumour diameter 27.5% of control) however, compared with those treated with ICR16 (mean tumour diameter 86% of control) .
  • the ICR62 treated tumours showed a more extensive host cell infiltrate surrounding the remaining viable tumour cells.
  • HN5 cells treated with antibodies to the EGFR undergo terminal differentiation.
  • Antibody ICR62 which binds to epitope C on the EGFR inhibits (a) the binding of ligand to the receptor, (b) the
  • a on the EGF receptor increases the binding of ligand (EGF and TGF ⁇ ) to the EGF receptor, (b) enhances the
  • EGF EGF induced proliferation of human fibroblasts, and (c) stimulates the growth of tumours over-expressing the EGF receptor (25) .
  • our aim was to discover if the monovalent Fab fragments of these mAbs were as effective as the bivalent mAbs in inducing these effects or if bivalent antibody was essential for their activity ( 2 , 3 , 5 , 7 , 44 , 45 ) .
  • a competitive RIA was used to determine the effect of the mAbs and their Fab fragments on the binding of 125 I-EGF and 125 I-TGF ⁇ to the EGFR on EJ cells as described (26) .
  • the rat mAbs 11/160 and ALN/11/53 directed against an irrelevant antigen (27) were used as controls.
  • 125 I-EGF was prepared as described above. EJ cells were seeded into 96 well plates (2xl0 4 cells/well) in DMEM containing 10% FCS. Following 48 hours incubation at 37°C, the cells were washed twice with ice cold binding buffer (DMEM, 15mM Hepes containing 0.1% BSA) and incubated with 20 ⁇ l of ICR9, Fab ICR9, ICR62 or Fab ICR62 (20 ⁇ g/ml) or medium alone for 30 minutes on ice prior to addition of 30 ⁇ l of 125 I-EGF (0.86-104nM) .
  • DMEM ice cold binding buffer
  • HSC-1, HSC-2, HSC-4, Ca9-22, LICR-L0N-HN5 and LICR-LON-HN6 cell lines (6,9) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal calf serum (FCS) and the antibiotics penicillin, streptomycin and neomycin.
  • DMEM Dulbecco's modified Eagle's medium
  • FCS foetal calf serum
  • DE532 cells (Flow Laboratories) seeded at 4 x 10 4 cells/ml in EMEM-10% FCS into 24-well plates were grown to confluence then the medium was replaced with EMEM-1%FCS. After 48 hours in this medium, 50 ⁇ l aliquot ⁇ of mAb or Fab fragment (25 ⁇ g/ml) and/or TGF ⁇ (5ng/ml) were added to triplicate wells and the cells were incubated overnight at 37°C then pulsed for 6 hours with 2 ⁇ Ci/well of 3 H-thymidine. The acid insoluble radioactivity incorporated into DNA was determined in a liquid scintillation counter.
  • Photomicrographs of HN5 tumour cells were taken following treatment for four days with 156nM of ICR62, ICR62 Fab fragment or control antibody 11/160 (27) , and viewed alternatively by phase contrast illumination or by immunofluorescent staining for expression of cytokeratin 10.
  • 5 x 10 4 HN5 cells were plated onto glass cover slips and placed in 24 well plates containing lml DMEM-2% FCS/well. Following overnight incubation at 37°C, specific or control antibodies (25 ⁇ g/ml) were added to the cultures and the cells were incubated for a further four days at 37°C.
  • the monovalent ICR62 inhibited the growth of five other head and neck tumour cell lines (HN5, HSC-1, HSC-2, HSC-4 and Ca9-22) (6,9) which overexpress the EGF receptor (figure 8) .
  • HN5 head and neck tumour cell lines
  • HSC-1, HSC-2, HSC-4 and Ca9-22 overexpress the EGF receptor
  • monovalent Fab fragments of this antibody also inhibited completely the TGF ⁇ induced proliferation of quiescent human foreskin fibroblasts ( Figure 9) .
  • the Fab of ICR62 was as effective as the bivalent antibody in inducing the differentiation of HN5 cells.
  • antigenic modulation wa ⁇ not a ⁇ ignificant factor in the escape of viable cells from antibody treatment and, providing antibody access wa ⁇ ⁇ ati ⁇ factory, the ⁇ e cells might be ⁇ u ⁇ ceptible to further treatment with antibody.
  • the intramolecular model suggests that binding of EGF to the EGF receptor induces a conformational change in the extracellular domain of a receptor monomer which is propagated across the plasma membrane to the cytoplasmic kinase domain leading to its activation (46,49).
  • the intermolecular model (2,3,48) on the other hand, propo ⁇ e ⁇ that receptor dimerization following ligand binding trigger ⁇ pho ⁇ phorylation by the cytopla ⁇ mic tyrosine kinase.
  • the second model it wa ⁇ expected that bivalent antibody would block activation by preventing receptor dimerization (3,7,8,44).
  • CDRs complementary determining regions
  • FR ⁇ framework regions
  • the ⁇ e CDRs can be grafted into the FRs of human antibodies, optionally with retention of selected murine re ⁇ idues in the FRs, according to well establi ⁇ hed principle ⁇ di ⁇ cus ⁇ ed above(see for example, Winter GB-A-2188638, Harris et al WO92/04381 and Queen et al, PNAS (1989), 86:10029-33) to create corresponding humanised antibodies which may be more appropriate for the treatment of humans.
  • tumours which expres ⁇ 10 s or le ⁇ receptor ⁇ are much le ⁇ ⁇ en ⁇ itive to antibody treatment than are the EGFR overexpressing tumour cells (1,26) .
  • Mendelsohn and colleagues in a preclinical study with chimpanzees have reported that treatment with a total dose of 650mg of antibody produced no toxicity (41) .
  • the aims of this clinical study were to (a) monitor patients for any possible signs of toxicity, (b) investigate if therapeutic antibody had localised specifically to tumour cell ⁇ in meta ⁇ tatic le ⁇ ion ⁇ , (c) determine the level of ICR62 remaining in circulation following treatment and (d) di ⁇ cover if the patient ⁇ mounted a human anti-rat antibody (HARA) re ⁇ pon ⁇ e.
  • HAA human anti-rat antibody
  • Patient ⁇ were con ⁇ idered eligible for inclu ⁇ ion in thi ⁇ trial who had i) inoperable hi ⁇ tologically or cytologically confirmed diagnosis of squamou ⁇ cell carcinoma of the lung or head and neck, ii) immunocytochemically proven expre ⁇ sion of the EGF receptor, iii) an ECOCG performance status of 0-2, iv) no known history of allergy or atopy, v) no immunological therapy within the previous 4 week ⁇ , vi) no significant abnormalities of renal, hepatic, or bone marrow function ( haemoglobin > lOg/dl, white count > 3xl0 9 /l / platelet > 120, creatinine ⁇ 130, liver enzymes and bilirubin ⁇ x2 normal) .
  • tumour grade and the previou ⁇ treatments that the patient ⁇ had received are ⁇ ummari ⁇ ed in Table 1.
  • Patient ⁇ were ⁇ kin te ⁇ ted (lOug intradermally) lhr before antibody wa ⁇ admini ⁇ tered and no patient was found to give an adverse respon ⁇ e.
  • Antibody in pho ⁇ phate buffered ⁇ aline pH 7.4 wa ⁇ given intravenou ⁇ ly a ⁇ a single bolus injection over a period of 30-60 minutes.
  • Groups of three patients were treated with 2.5, 10, 20, or 40mg of ICR62 and a further eight patients were given lOOmg of this antibody. All patients were evaluated for ⁇ igns of toxicity.
  • the amount of free mAb ICR62 pre ⁇ ent in ⁇ erum wa ⁇ determined by its ability to inhibit the binding of EGF or TGF to the bladder carcinoma cell line EJ as described previously (27) .
  • Doubling dilutions of serum (50 ⁇ l) were mixed with an equal volume of 125 I-EGF (4xl0 4 cpm) or 125 i- TGF (4xl0 4 cpm) .
  • Standards containing known concentrations of ICR62 were set up in the same way. Aliquots of 90 ⁇ l of each mixture were then transfered to monolayers of EJ cells grown to confluency in 96 well plates.
  • tumour biopsies were snap frozen in liquid nitrogen then mounted in OCT medium and sections of 5 ⁇ m thicknes ⁇ cut.
  • a second sample was fixed in acetone at 4°C for 10 minutes, then after wa ⁇ hing briefly in PBS the ⁇ ection wa ⁇ incubated with mAb ICR62 (lOO ⁇ g/ml, for 1 hour. Following washing in PBS for 5 minutes, the sections were incubated with a 1:100 dilution of sheep anti-rat F(ab')2 conjugated to horse radish peroxidase (Amersham) for 45 minutes.
  • Peroxidase staining was demonstrated by incubating the section ⁇ for 10 minute ⁇ in a ⁇ olution containing 0.05% diaminobenzidine (Sigma), 0.1% hydrogen peroxide (Merck) and 0.07% imidazole (Merck) . After wa ⁇ hing in running tap water for 5 minute ⁇ , the sections were counterstained in Mayer' ⁇ Haematoxylin (HD Supplier ⁇ ) for 30 seconds. Finally the section ⁇ were dehydrated, cleared and mounted.
  • biopsie ⁇ were taken from metastatic sites, 24 hours after the antibody was administered, then frozen sections were cut and stained with sheep anti-rat antibody alone.
  • serial section ⁇ taken from the ⁇ ame biop ⁇ ies were stained first with ICR62 followed by the peroxidase conjugated sheep anti rat F(ab')2 so that all EGFR expressing cells were stained.
  • Patient ⁇ were admitted to ho ⁇ pital on the day before the admini ⁇ tration of antibody and their biochemical and haematological parameters were monitored. Following intravenou ⁇ injection of the antibody some of the patients exhibited mild rigors and fever or hypotension (Table 1) . The symptom ⁇ which were not related to the do ⁇ e of antibody admini ⁇ tered were readily controlled. In no ca ⁇ e were any ⁇ evere toxicitie ⁇ observed. The patients were released from hospital 24 hours after the injection of antibody and they were seen at weekly intervals for up to six weeks. None of the patients reported any untoward effects of their treatment during the follow-up period.
  • the level of ICR62 remaining in circulation wa ⁇ found to be highe ⁇ t in patient ⁇ recieving lOOmg of ICR62. In one patient, about half of the antibody admini ⁇ tered wa ⁇ in circulation on day 3 but no free mAb could be detected in the blood at 7 days post ICR62 treatment.
  • Injected ICR62 binds to the EGFR on tumour cell membranes
  • Biopsie ⁇ were taken of meta ⁇ tatic le ⁇ ions from six patient ⁇ , 24 hours after treatment of the patients with 40mg or lOOmg of ICR62. Frozen ⁇ ections were examined for the presence of cell bound antibody by staining directly with a peroxidase-conjugated second antibody reagent. Two of the biopsie ⁇ were found to con ⁇ ist largely of necrotic material and were discarded but four yielded well defined regions containing infiltrating tumour. The sections illustrated in figure 2a show that 24 hours after treatment of two patients with 40mg of ICR62, the antibody had localized to the membranes of tumour cells in the metastatic sites and the proliferating cells at the periphery of the tumour were strongly stained.
  • ICR62 ( Table 1, Figure 4) .
  • Sera from two out of the eight patient ⁇ treated with lOOmg of ICR62 (patients 16 and 19) contained antibodies directed against determinants on the constant region since they bound to the Fab and intact antibody but not to the ICR62 scFv (Table 1, Figure 5) .
  • the results obtained with the serum taken before treatment indicated that antibodies which bound to rat IgG were present in the sera before ICR62 was administered but test ⁇ were not done to determine if binding wa ⁇ ⁇ pecific or due to the presence of autoantibodies such as rheumatoid factor.
  • mice antibodies have undergone clinical evaluation in Phase I and Phase II ⁇ tudies in patients with head and neck, lung or brain cancers including mAb EGFR1 (52,53), mAbs 225 and 528 (42,54), mAb 425 (EMD 55900 E Merk, 55-59) and mAb RG83852 (60) .
  • the aim of these studie ⁇ like the one pre ⁇ ented here, wa ⁇ to determine whether treatment of cancer patient ⁇ with anti- EGFR mAbs produced life threatening toxicities by binding to the EGFR expre ⁇ sed by normal tis ⁇ ue ⁇ including liver and ⁇ kin.
  • the re ⁇ ult ⁇ of the ⁇ e ⁇ tudie ⁇ have ⁇ hown that mouse antibodies to the EGFR can be given safely to patients without toxicity.
  • Divigi and colleagues have treated patients with advanced ⁇ quamou ⁇ cell carcinoma of the lung with ⁇ ingle do ⁇ e ⁇ of up to 300mg of mAb 225, including 4mg of indium Ill-labeled 225, without any sign of toxicity (42) .
  • mAb ICR62 for a phase I clinical study since it was the most effective of a large number of rat mAbs we had made again ⁇ t the human EGFR, at inducing the regre ⁇ ion of xenograft ⁇ of head and neck, vulva and breast carcinomas grown in athymic mice (39,50,51) .
  • the results of this Phase I clinical study has indicated that mAb ICR62 can be given safely, at doses up to lOOmg, to cancer patients without any life threatening toxicities. This finding is in agreement with the re ⁇ ult ⁇ of studies with mouse antibodies to the EGFR described above.
  • the results of this Phase I dose escalation study has indicated that the rat mAb ICR62, which acts as an EGF and TGF antagonist, a) can be adminstered safely in patients with squamou ⁇ cell carcinoma, b) localize ⁇ efficently to meta ⁇ tatic sites in patients with squamous cell carcinoma, and c) may therefore be useful in the treatment of a significant number of cancer patient ⁇ who ⁇ e tumour ⁇ overexpre ⁇ the EGF receptor. From the re ⁇ ult ⁇ of our preclinical ⁇ tudie ⁇ in athymic mice, we have noted that to achieve tumour de ⁇ truction repeated admin ⁇ tration of EGFR mAb ⁇ may be required. For thi ⁇ rea ⁇ on, a phase II clinical study is planned using multiple do ⁇ e ⁇ of mAb ICR62.
  • EGFR in human esophageal carcinoma cells act as ' a autocrine growth factor.
  • Bilzer T Stassiecki P
  • Vega F et al : Immunotherapy of malignant gliomas with the anti-EGFR monoclonal antibody. Proc Annu Meet Am Assoc Cancer Res,
  • AAG TTC AAG AGC AAG GCC ACA TTG ACT GCA GAC AAA TCC ACC GAT ACA GCC TAT ATG GAG
  • GGA GAA GCT CCC AAA CGC CTG ATA TAT : AAT ACA AAC AAT TTG CAA ACA GGC ATC CCA TCA Gly Glu Ala Pro Lys Arg Leu He Tyr Asn Thr Asn Asn Leu Gin Thr Gly He Pro Ser

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention relates to the development of agents and methods for treating tumour cells. More particularly, it is concerned with antibodies against the epidermal growth factor receptor (EGFR), which have been found to exhibit an antitumour effect, inducing terminal differentiation in tumour cells, especially those which are characterised by over-expressing EGFR. Included in the invention are these antibodies and their functional equivalents, mutants and derivatives. The antibodies may be murine (rat or mouse), but preferably have framework regions and/or constant regions based on or derived from human antibodies. The present invention also discloses that fragments of these antibodies (eg Fabs) can retain the properties of the complete antibody. The antibodies are useful, e.g. in treating or detecting tumour cells and in targeting therapies.

Description

ANTIBODIES TO EGF RECEPTOR AND THEIR ANTITUMOUR EFFECT
Field of the Invention
This invention relates to the development of agents and methods for treating tumour cells. More particularly, it is concerned with antibodies against the epidermal growth factor receptor (EGFR) , which have been found to exhibit an antitu our effect.
Background to the Invention
There is increasing evidence to suggest that polypeptide growth factors and their receptors are involved not only in the regulation of normal cell proliferation and differentiation but also, when aberrantly expressed, in the pathogenesis of certain types of human malignancy. The epidermal growth factor receptor (EGFR) and its ligands is one such example. This receptor is a 170 D transmembrane glycoprotein with tyrosine kinase activity which transmits the mitogenic action of the EGF family of growth factors including EGF, TGFα and amphiregulin. The binding of these ligands to the external domain of the EGF receptor initiates a number of early and delayed responses in the target cells leading ultimately to DNA synthesis and cell division.
Over-expression of the EGFR has been reported in a number of human malignancies including cancer of the breast, brain, bladder, head and neck, pancreas and lung (1,9-12) .
High levels of expression of this receptor have also been associated with poor survival in some of these patients
(1,12,13). In addition, the histological and biological examination of human tumour biopsies and cell lines has shown that overexpression of the EGF receptor is often accompanied by the production of one or two of its ligands (TGFα and/or EGF) by the same tumours, suggesting that an autocrine loop may be responsible for growth of tumours of this type (14-17) . Furthermore, since the ligand-induced activation of such cells acts primarily via receptors on the cell surface rather than intracellularly, such a system may form a suitable target for monoclonal antibody directed therapy (1,18-24) . We have described recently the production of 21 rat monoclonal antibodies raised against five distinct epitopes on the external domain of the human EGF receptor using as immunogen LICR-LON-HN5, a squamouε cell carcinoma of head and neck, MDA-MB 468, a breast carcinoma cell line or A431, an epidermoid carcinoma cell line (1,25,26) . Our aim was to obtain as diverse a population (isotype/epitope) of antibodies as possible from which the best mAb or combination of mAbs for clinical and diagnostic application could be selected.
Of these antibodies ICR64 (IgGl,) directed against epitope D and ICR16 (IgG2a) and ICR62 (IgG2b) both directed against epitope C were (in that order) the most effective at inhibiting ligand binding and the growth in vitro of squamous cell carcinomas overexpressing the EGFR. However, ICR62 was the most effective of the three antibodies in inducing the regression of xenografts of such tumours growing in athymic mice.
Summary of the Invention
Here we describe the results of an immunohistological examination of the events occurring in tumours during regression where athymic mice bearing established xenografts had been undergoing mAb therapy. Our aim was to investigate (a) the mechanism by which antibodies to the EGFR inhibited tumour growth and (b) to determine if viable tumour cells were present in the residual tumour nodules following treatment with antibody, and if so to determine if loss of antigen expression was a significant factor in the escape of these tumour cells. The results of initial experiments suggested that prolonged exposure of xenografts of the HN5 tumour (a squamous cell carcinoma) which overexpresses the EGF receptor to monoclonal antibody ICR62 (IgG2b) induces a complete regression of the xenograft if antibody treatment commenced at the time of tumour implantation. Even where treatment was delayed until tumours were established, ICR62 induced complete or almost complete regression of the tumours (39) .
Histological examination of the tumours remaining at the end of the experiment showed that, while few viable tumour cells could be detected, numerous keratinised areas were observed, suggesting that only differentiated tissues remained (39) . The applicants have now investigated the possibility that receptor blockade induces terminal differentiation (ie the cellular reversion to normal phenotype) of squamous cell carcinomas which overexpress the EGF receptor. Accordingly, in a first aspect, the present invention provides antibodies to EGF receptor, and fragments thereof, for therapeutic use. Included in this aspect of the invention are those antibodies identified herein, and their functional equivalents, mutants and derivatives. The antibodies may be murine (rat or mouse) , but preferably have framework regions and/or constant regions based on or derived from human antibodies. The antibodies may be complete immunoglobulin molecules, but they may be Ig fragments, for example monovalent or divalent Ig entities such as Fab fragments, single chain Fv molecules etc.
In a further aspect, the present invention discloses the use of antibodies to the EGFR, or fragments thereof, in the preparation of a medicament for inducing terminal differentiation in tumour cells, especially those which are characterised by over-expressing EGFR. In a further aspect, the present invention provides DNA encoding the above antibodies, expression vectors comprising that DNA and host cells transformed with the expression vectors.
In a further aspect, the present invention provides pharmaceutical compositions comprising one or more of the above antibodies, for example selected from antibodies ICR16, ICR62 and ICR64. The amounts of the antibodies used in the compositions can be determined by the skilled person, and will be typically in the range 1 to 300mg. Optionally, the the above antibodies or fragements can be conjugated to a label, toxin or drug. Alternatively, the antibodies could be used to target an active agent administered in a precursor form to cells, for conversion to the active form by an activating agent produced in, or targeted to, the cells to be treated. This type of approach is sometimes known as ADEPT (see for example, EP-A-415731 and WO 90/07936) .
Also included are peptide or mimetic molecules which mimic the antibody binding to EGFR and likewise induce terminal differentiation of tumour cells. The present invention also includes the use of the above antibodies in the design or synthesis of these mimetics.
Although the EGF receptor antibodies mentioned above are primarily of interest in the treatment of tumour cells, they may also find applications in the treatment of other disorders, eg arthritis, psoriasis, atherosclerosis, S E, inflammation or other proliferative disorders.
Modified Antibodies
The antibodies described above can altered in a variety of ways using recombinant DNA technology coupled with advances in the field of monoclonal antibody and protein engineering. This has enabled access to a large selection of antibodies and antibody fragments with different properties and structures to natural antibodies.
The production of monoclonal antibodies is well established in the art. Monoclonal antibodies can be subjected to the techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which retain the specificity of the original antibody. Such techniques may involve introducing DNA encoding the immunoglobulin variable region, or the complementarity determining regions (CDRs) , of an antibody to the constant regions, or constant regions plus framework regions, of a different immunoglobulin. See, for instance, EP-A-184187, GB 2188638A or EP-A-239400. A hybridoma producing a monoclonal antibody may be subject to genetic mutation or other changes, which may or may not alter the binding specificity of antibodies produced. As an alternative or supplement to immunising a mammal with a peptide, an antibody specific for a protein may be obtained from a recombinantly produced library of expressed immunoglobulin variable domains, eg using lambda bacteriophage or filamentous bacteriophage which display functional immunoglobulin binding domains on their surfaces; for instance see WO92/01047. The library may be naive, that is constructed from sequences obtained from an organism which has not been immunised with the target, or may be one constructed using sequences obtained from an organism which has been exposed to the antigen of interest
(or a fragment thereof) .
Antibodies may be modified in a number of ways. Indeed the term "antibody" should be construed as covering any specific binding substance having an binding domain with the required specificity. Thus this term covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, including any polypeptide comprising an immunoglobulin binding domain, whether natural or synthetic. Chimaeric molecules comprising an immunoglobulin binding domain, or equivalent, fused to another polypeptide are therefore included. Cloning and expression of chimaeric antibodies are described in EP-A- 0120694 and EP-A-0125023.
It has been shown that fragments of a whole antibody can perform the function of binding antigens. Examples of binding fragments are (i) the Fab fragment consisting of VL, VH, CL and CHI domains; (ii) the Fd fragment consisting of the VH and CHI domains; (iii) the Fv fragment consisting of the VL and VH domains of a single antibody; (iv) the dAb fragment (Ward, E.S. et al. , Nature 341, 544-546 (1989)) which consists of a VH domain; (v) isolated CDR regions; (vi) F(ab')2 fragments, a bivalent fragment comprising two linked Fab fragments (vii) single chain Fv molecules (scFv) , wherein a VH domain and a VL domain are linked by a peptide linker which allows the two domains to associate to form an antigen binding site (Bird et al, Science, 242, 423-426, 1988; Huston et al, PNAS USA, 85, 5879-5883,
1988) ; (viii) bispecific single chain Fv dimers
(PCT/US92/09965) and (ix) "diabodies", multivalent or multispecific fragments constructed by gene fusion
(W094/13804; P. Holliger et al Proc. Natl. Acad. Sci. USA 90 6444-6448, 1993) .
Diabodies are multimers of polypeptides, each polypeptide comprising a first domain comprising a binding region of an immunoglobulin light chain and a second domain comprising a binding region of an immunoglobulin heavy chain, the two domains being linked (eg by a peptide linker) but unable to associate with each other to form an antigen binding site: antigen binding sites are formed by the association of the first domain of one polypeptide within the multimer with the second domain of another polypeptide within the multimer (WO94/13804) . Where bispecific antibodies are to be used, these may be conventional bispecific antibodies, which can be manufactured in a variety of ways (Holliger, P. and Winter G. Current Opinion Biotechnol. 4, 446-449 (1993)), eg prepared chemically or from hybrid hybridomas, or may be any of the bispecific antibody fragments mentioned above. It may be preferable to use scFv dimers or diabodies rather than whole antibodies. Diabodies and scFv can be constructed without an Fc region, using only variable domains, potentially reducing the effects of anti-idiotypic reaction. Other forms of bispecific antibodies include the single chain "Janusins" described in Traunecker et al, Embo Journal, 10, 3655-3659, (1991) . Bispecific diabodies, as opposed to bispecific whole antibodies, are also particularly useful because they can be readily constructed and expressed in E. coli . Diabodies
(and many other polypeptides such as antibody fragments) of appropriate binding specificities can be readily selected using phage display (WO94/13804) from libraries. If one arm of the diabody is to be kept constant, for instance, with a specificity directed against antigen X, then a library can be made where the other arm is varied and an antibody of appropriate specificity selected.
Previously, bispecific antibodies incorporating a specificity for the T-cell co-receptor CD3 have been shown to inhibit tumour growth (Titus, J. A. et al. , J. Immunol. 138, 4018-4022 (1987)) and to cure lymphoma (Brissinck J. et al, J. Immunol. 174, 4019-4026 (1991)).
It may be desirable to "humanise" non-human (eg murine) antibodies to provide antibodies having the antigen binding properties of the non-human antibody, while minimising the immunogenic response of the antibodies, eg when they are used in human therapy. Thus, humanised antibodies comprise framework regions derived from human immunoglobulins
(acceptor antibody) in which residues from one or more complementary determining regions (CDR's) are replaced by residues from CDR's of a non-human species (donor antibody) such as mouse, rat or rabbit antibody having the desired properties, eg specifici .y, affinity or capacity. Some of the framework residues of the human antibody may also be replaced by corresponding non-human residues, or by residues not present in either donor or acceptor antibodies. These modifications are made to the further refine and optimise the properties of the antibody.
Brief Description of the Drawings
Figures 1 and 2 show flow cytometric analysis of DNA in nuclei obtained from HN5 cells following four days incubation in vitro in DMEM-2%FCS alone or in DMEM-2%FP" containing anti-EGFR mAbs (156nM) or EGF (lOnM) . Fi_, shows DNA histograms; Fig 2 shows the percentage of cells in each phase. Figures 3 and 4 show the influence of antibodies to the EGFR or their Fab fragments on the binding of 125I-EGF (Fig 3) or 125I-TGFα (Fig 4) to the human bladder carcinoma cell line EJ.
Figures 5 and 6 show Scatchard plots of 12SI-EGF binding to EJ cells in the absence or presence of monovalent and divalent mAbs ICR9 (Fig 5) and ICR62 (Fig 6) . Figures 7-9 show the effect of treatment with antibodies to the EGFR or their Fab fragments on the growth in vitro of HN6 cells (Figs 7) , other head and neck carcinoma cell lines overexpresεing the EGF receptor (Fig 8) , and the TGFα induced proliferation of quiescent human foreskin fibroblasts (Fig 9) .
Figure 10 shows titration curves showing the inhibition of binding of 1251-EGF to EJ cells by serum taken at the times indicated. A, patient 8 (20mg) ; B, patient 10 (40mg) ; or C, patient 13 (lOOmg) . The starting concentration of the ICR62 standard was lOug/ml.
Figure 11 shows the development of human anti-rat antibodies in the serum of patient number 9 following injection of 20mg ICR62 shown by binding to intact ICR62 (A) , Fab ICR62 (B) and scFv ICR62 (C) .
Figure 12 the development of human anti-rat antibodies in the serum of patient number 11 following injection of 40mg of ICR62 shown by binding to intact ICR62 (A) , Fab ICR62 (B) but not scFv ICR62 (C) .
The sequence listings show the DNA and deduced amino acid sequences of the variable regions of the heavy and light chains of ICR62 and ICR64, with the CDRs indicated in square brackets.
Detailed Description Experiments
Part 1. Investigation of cell lines in vitro and of human tumour xenografts in vivo during or following treatment with several antibodies to the EGFR
Materials and methods
Cell lines. The head and neck carcinoma cell line LICR-LON-HN5 and the breast carcinoma cell line MDA-MB 468 were cultured routinely in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal calf serum (FCS) and the antibiotics penicillin, streptomycin and neomycin. For growth inhibition assays the concentration of FCS in medium was reduced to 2% to minimize the effects of any growth factors present.
Monoclonal Antibodies. The preparation of rat monoclonal antibodies to the extracellular domain of the human EGFR has been described previously (25,26) . ICR16 (IgG2a) was raised against the receptor on the squamous cell carcinoma HN5 while mAbs ICR62 (IgG2b) , ICR61 (IgG2b), and ICR64 (IgGl) were raised against the receptor on the breast carcinoma cell line MDA-MB 468. Antibodies ICR16 and ICR62 bind to epitope C and antibodies ICR61 and ICR64 bind to another distinct epitope D on the external domain of the EGF receptor. Isotype matched control antibodies included ALN/ll/53 (IgG2a) and 11/160 (IgG2b) which are directed against a specific antigen on the rat sarcoma HSN (27) , or RCI/4/74 (IgGl) an antibody directed against an idiotopic determinant on ICR16 (unpublished data) . Monoclonal antibody to cytokeratin 10 (R SE-60) was obtained from EuroPath Ltd, Cornwall. Mouse monoclonal antibody to involucrin (28) was a gift from Dr Fiona Watt (Imperial Cancer Research Fund, London) .
Treatment of mice bearing human tumour xenografts with antibodies to the EGFR.
Xenografts of human tumours were established in athymic (nu/nu) mice and treated with antibodies as described previously (29,39) . Briefly, the protocols used were as follows.
A) MDA-MB 468 xenografts. Three groups of four mice were inoculated in both flanks with 5 x 106 tumour cells. On the day of tumour inoculation (day 0) one group of mice was injected i.p with ICR62, the second with ICR16 and the third with control antibody. Treatment with antibody (20μg/dose) was continued for a further 4 consecutive days and thereafter three times weekly until day 18 (total dose 0.44mg/mouse) . Animals were observed for up to 100 days when the experiment was terminated and the tumour nodules remaining were excised, weighed and fixed for histological examination (see below) .
B) HN5 xenografts Since treatment of athymic mice with antibody initiated at the time of tumour inoculation results in complete and permanent regression of these tumours (39) , HN5 tumour xenografts were set up as described above but the commencement of treatment with antibodies to the EGFR was delayed until the tumours had reached a mean diameter of about 0.5cm. In this experiment groups of four to five mice were treated with antibodies ICR61 or ICR64, or with combinations of ICR61 plus ICR62 or ICR64 plus ICR62; pairs which do not compete for binding to the EGFR. In each case a second group of mice was treated with control antibodies or saline. Treatment with antibodies (200μg/dose) was for five consecutive days and thereafter three times weekly until the day indicated in each experiment (total dose 2.2mg/mouse) . Animals were observed for up to 100 days or killed when the tumours reached a mean diameter of 0.8-1.0cm.
Ξistological examination of human tumour xenografts following treatment with antibodies.
Two protocols were used for examination of tumour specimens.
For routine histological examination, tumours were excised and samples were fixed in Methacarn and then embedded in paraffin. Four micron sections were cut and stained with haematoxylin and eosin (H & E) .
All immunohistochemical studies of human tumour xenografts were performed by the indirect method using immunoperoxidase-conjugated F(ab')2 rabbit anti-rat Ig as the second reagent (Star 51, Serotec Ltd, Oxford) . This antibody had been preadsorbed to remove all reactivity with mouse immunoglobulins. Samples of tumour tissue were snap frozen in isopentane precooled to liquid nitrogen temperature. Sections of 5μm thickness were cut on a cryostat and mounted on glass slides that had been coated previously with 1% aminopropyltriethoxy-saline (Sigma, A3648) in acetone. Slides were dried at 37°C (30 minutes), fixed in formol-calcium for 5 minutes, and immersed in ice cold choloroform/acetone (1:1) for 5 minutes. After three washes with PBS, endogenous peroxidase was blocked by immersing the sections for 10 minutes in PBS containing 3% H202. The sections were incubated first with rat antibodies to the EGFR (l-20μg/ml, 90 minutes at room temperature) then, after three washes in PBS, with lOOμl of a 1/100 dilution of immunoperoxidase conjugated F(ab')2 rabbit anti-rat IgG (in PBS-0.5% BSA) for 90 minutes at room temperature. After washing twice with PBS and twice in DDW bound peroxidase was visualized using diamino-benzidine
(DAB) [lOOmg DAB in 100ml of 0.1 M Tris buffer pH7.2, 100ml H20, 66μl H202] . After 5 minutes incubation, the sections were washed twice in DDW, counterstained in Mayer's haemalum for 1 minute, dehydrated by passing through graded alcohols then mounted in DPX. In some cases, where xenografts had been treated with antibody to the EGFR, staining of the frozen sections was performed as above but without incubation in the primary antibody in order to visualize the presence of any remaining therapeutic mAb.
Flow cytometric analysis of tumour cells following treatment with antibody.
HN5 cells (7.5 x 10s) were seeded into 25cm2 Nunc flasks (Gibco Europe Ltd, Scotland) containing 15ml DMEM plus 2%
FCS. Monoclonal antibody (25μg/ml) , EGF (lOnM) or the equivalent amount of medium only was then added and the cultures were incubated for four days at 37°C. Flow cytometric analysis of the nuclei prepared from these cells was performed essentially as described by Ormerod et al (30) . Briefly, a suspension of single cells from each flask was prepared in 200 μl of PBS and this was followed by the vigorous addition of 2ml ice cold 70% ethanol-30% PBS. The cells were incubated for at least 30 minutes at 4°C, harvested by centrifugation and resuspended in 700μl PBS. Following the addition of lOOμl of RNAse (lmg/ml, Sigma) and 200μl of propidium iodide (lOOμg/ml, Sigma) the suspension was incubated first at 37°C for 30 minutes and then on ice for 90 minutes. The nuclei were analysed using an Ortho Cytofluorograph 5OH equipped with a Spectra-Physics argon-ion laser producing 200mW at 488nm and an Ortho 2150 computer system (30) .
Immunofluorescent staining of cytokeratin 10 and involucri .
5xl04 HN5 cells were plated onto glass cover slips in 24 well plates containing 1ml DMEM plus 2%FCS. Following overnight incubation at 37°C, specific or control antibodies (25 μg/ml) or medium alone were added to the cultures and the cells were incubated for a further three to four days at 37°C. After two washes with PBS, the cells were fixed for 5 minutes in ice-cold methanol then washed by incubation in PBS for 30 minutes. Mouse anti-cytokeratin 10 or anti-involucrin mAb diluted in PBS-0.5% BSA was added and the coverslips were incubated at 4°C for 1 hour. After three washes, bound primary antibody was detected using fluorescein-conjugated sheep anti-mouse Ig (Amersham International) . The coverslips were mounted in Hydromount: glycerol (1:1) and examined for green fluorescence using a Zeiss Axiovert 100 microscope.
Results
Histological examination of regressing tumours.
H & E staining
We have shown previously that when athymic mice bearing xenografts of the breast carcinoma MDA-MB 468 were treated from day 0-18 with a total dose of 440μg of ICR16 (IgG2a) , half of the tumours regressed completely but small static nodules persisted at the remaining sites when the experiment was terminated on day 100 (39) . However, the present experiments showed that similar treatment with mAb ICR62 (IgG2b) resulted in complete eradication of all tumours. Histological examination of H&E stained sections of the tumour nodules remaining following treatment with ICR16 showed that a few areas contained apparently viable tumour cells amongst the largely necrotic zones. The necrotic cells also showed substantial loss of cytoplasmic staining following treatment with ICR16 compared with the progressively growing tumours treated with control antibody.
We have also examined HN5 tumour xenografts following treatment with one, or a combination of two anti-EGFR mAbs that bind to two distinct epitopes on the external domain of the human EGF receptor. When athymic mice bearing HN5 xenografts were treated from day 7-24 with a combination of ICR62 plus ICR64 (total dose 2.2mg/mouse) , on termination of the experiment (day 79) complete control was observed at 2/10 sites and the tumour nodules remaining were still undergoing regression (29) . Histological examination of these tumour nodules showed the presence of few if any viable cells and the lesions were composed largely of scar tissues compared to tumours that were growing in animals treated with the control antibody.
Similarly, when HN5 tumour xenografts were treated from day 5-24 with antibody ICR61, 2/8 tumours had disappeared completely when the experiment was terminated on day 75 (29) . Examination of the nodules remaining also showed that few if any viable cells were present and the lesions were similar in appearance to those described above. An H & E stained section of an HN5 nodule remaining after treatment from day 7-24 with a combination of ICR61 plus ICR62 (total dose 2.2mg/mouse) showed that zones of keratinisation and apparent squamous differentiation were present. Indeed, keratinized areas could be found in all of the tumour lesions remaining in mice that had undergone treatment with the specific antibodies used either alone or in combination. These findings suggest that squamous differentiation of HN5 was an important consequence of treatment with EGFR-specific antibodies.
Immunoperoxidase staining
An integral part of this study was to determine if any viable tumour cells remained after treatment with anti-EGFR antibody that continued to express high levels of the EGFR or if loss of this antigen could contribute to their escape. While none of the rat mAbs used in this study bind to the EGFR in formalin-fixed paraffin embedded sections, they are all effective in staining the membranes of cryopreserved tissues. Strong membrane reactivity was obtained when frozen sections of HN5 tumour xenografts were stained with specific antibody. No staining was obtained if treatment with specific antibody was omitted or when the sections were pretreated with control antibody.
We have shown previously that when athymic mice bearing xenografts of the HN5, A431 or MDA-MB 468 tumours were treated with antibody ICR62, the tumours regressed more rapidly, (and in most cases completely) , compared with the same tumours treated with mAbs ICR16 or ICR64 (39) . We have carried out an immunohistochemical investigation of regressing tumours to determine the reasons for the greater efficiency of antibody ICR62 in vivo. First, athymic mice bearing HN5 xenografts were treated for a short period (days 0-4) with either ICR16 or ICR62. On day 7 tumours were excised, cryosections were prepared and stained with peroxidase conjugated F(ab')2 rabbit anti-rat IgG. The uniform staining of the tumour cell membranes with the second antibody, shows that all of the tumour cells were coated with specific rat antibody at this time. The total area of tumour remaining was smaller in the mice treated with ICR62 (mean tumour diameter 27.5% of control) however, compared with those treated with ICR16 (mean tumour diameter 86% of control) . Also, the ICR62 treated tumours showed a more extensive host cell infiltrate surrounding the remaining viable tumour cells.
Finally, we have examined the residual nodules at day 101 after mice bearing established xenografts of the HN5 tumour were treated with ICR64 from day 7-24. Despite the fact that the last treatment with antibody was given 77 days previously, staining of the sections with peroxidase conjugated anti-rat Ig showed that significant amounts of rat mAb remained associated with the dead cells and the keratinized areas where tumour destruction was complete. Since the second antibody used was a F(ab')2 preparation that had been pre-adsorbed against mouse Ig the staining could not have been due to non-specific binding to mouse Ig or Fc-receptor bearing cells. In contrast, the small areas of viable tumour did not stain, suggesting either that ICR64 had not reached these locations or that it had been lost from the cell membranes during cell proliferation. To determine if these cells still overexpressed the EGFR, consecutive sections were treated first with ICR64 and then with the peroxidase conjugated second antibody. Here, the nests of viable cells stained positively suggesting that loss of antigen was not a significant factor in the escape of these cells from antibody treatment.
HN5 cells treated with antibodies to the EGFR undergo terminal differentiation.
The finding of keratin whorls in tumour nodules remaining after antibody treatment was of particular interest. We have shown previously that, at concentrations above 5nM, mAbs ICR16, ICR62 and ICR64 inhibit completely the growth of HN5 cells cultured in medium containing 2% FCS (25,26) . To investigate the possibility that terminal differentiation could be a pathway for tumour cell inactivation we have determined the cell cycle characteristics of growth arrested cells and examined them for expression of the differentiation markers involucrin (31-33) and cytokeratin 10 (34,35).
Growth arrested HN5 cells accumulate in G0/G1.
Flow cytometric analysis of nuclei following treatment of HN5 cells with either antibodies to the EGFR (156nM ICR16 or ICR62) or with the ligand EGF (lOnM) is illustrated in Figures 1 and 2. After treatment with doses of anti-EGFR mAbs which inhibited completely the growth of HN5 cells, the numbers of cells in S and G2/M had decreased substantially compared with the controls growing in medium alone, and most of the cells were arrested in G0/G1. Treatment with EGF at a concentration (lOnM) which also inhibited (but not completely) the growth of HN5 cells, also resulted in a decrease in the percentage of cells in both S and G2/M phases of cell cycle but to a lesser extent than following treatment with the mAbs. We did not see any evidence for DNA fragmentation in a pre-Gl peak indicative of apoptosis (figure 1) .
Growth arrested HN5 cells synthesize markers of terminal differentiation.
When HN5 cells were incubated for four days with 156nM of the anti-EGFR mAbs most of the cells were found to express the differentiation marker cytokeratin 10 as visualised by immunofluorescence with mAb RKSE-60. The proportion of positive cells varied with the anti-EGFR antibody used, the most effective being ICR64, and by day 4 the majority of the treated cells were strongly positive for this differentiation marker. In addition the majority of cells expressing cytokeratin 10 were larger than the cytokeratin negative cells. Similar results were obtained when the treated HN5 cells were stained with antibody to another differentiation marker, involucrin.
Essentially identical results were obtained when HN5 cells were treated with ICR16 or ICR62 and examined for CK10 and involucrin expression (data not shown) . However, neither differentiation marker was expressed by cells that had been grown to near confluence in medium alone or with control antibody although these cultures contained approximately ten times more cells than in the wells treated with antibodies to the EGFR.
Part 2 Further investigation of the mechanism of action of the antibodies and their Fab fragments
Antibody ICR62, which binds to epitope C on the EGFR inhibits (a) the binding of ligand to the receptor, (b) the
EGF and TGFα induced proliferation of human fibroblasts and
(c) the growth of a range of human tumour cells that overexpress the EGFR (26) . Antibody ICR9 binds to epitope
A on the EGF receptor, and (a) increases the binding of ligand (EGF and TGFα) to the EGF receptor, (b) enhances the
EGF induced proliferation of human fibroblasts, and (c) stimulates the growth of tumours over-expressing the EGF receptor (25) . Here, our aim was to discover if the monovalent Fab fragments of these mAbs were as effective as the bivalent mAbs in inducing these effects or if bivalent antibody was essential for their activity ( 2 , 3 , 5 , 7 , 44 , 45 ) .
Methods Referring to Figures 3 and 4; monoclonal antibodies ICR9 and ICR62, and their Fab fragments, were prepared as described previously (25,26,36) . Fab fragments of ICR9 and ICR62 were prepared by papain digestion and purified by gel and affinity chromatography. Analysis by SDS-PAGE indicated that the Fab preparations were free of contaminating intact antibody (data not shown) . Human recombinant EGF and TGFα (Collaborative Research, Waltham, Mass) were labelled with Iodine-125 (Na125I, Amersham International) using IODO-GEN, to a specific activity of lOμCi/μg as described previously (25) . A competitive RIA was used to determine the effect of the mAbs and their Fab fragments on the binding of 125I-EGF and 125I-TGFα to the EGFR on EJ cells as described (26) . The rat mAbs 11/160 and ALN/11/53 directed against an irrelevant antigen (27) were used as controls.
Referring to Figs 5 and 6; 125I-EGF was prepared as described above. EJ cells were seeded into 96 well plates (2xl04 cells/well) in DMEM containing 10% FCS. Following 48 hours incubation at 37°C, the cells were washed twice with ice cold binding buffer (DMEM, 15mM Hepes containing 0.1% BSA) and incubated with 20μl of ICR9, Fab ICR9, ICR62 or Fab ICR62 (20μg/ml) or medium alone for 30 minutes on ice prior to addition of 30μl of 125I-EGF (0.86-104nM) . Following a further 5 hours incubation on ice, the cells were washed three times with binding buffer, lysed and the bound radioactivity was determined. Non-specific binding was corrected by subtracting the counts bound in the presence of a 100-fold excess of cold EGF and was less than 6% of the total counts bound. Each value is the mean of triplicate samples.
Referring to Figures 7 and 8; HSC-1, HSC-2, HSC-4, Ca9-22, LICR-L0N-HN5 and LICR-LON-HN6 cell lines (6,9) were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal calf serum (FCS) and the antibiotics penicillin, streptomycin and neomycin. To investigate the effect of treatment with intact mAbs or their Fab fragments on the growth of the tumour cells in vitro about 5xl03 cells in lOOμl of DMEM containing 2% FCS were seeded into each well of a 96-well plate. After incubation for 4 h at 37°C, lOOμl aliquots of dilutions of mAbs or Fab fragments were added to triplicate wells and the cultures were incubated at 37°C. When the cells in the control wells (containing medium alone) were nearly confluent, all cells were fixed, stained with methylene blue and the A620 determined as described previously (26) .
Referring to Figure 9; DE532 cells (Flow Laboratories) seeded at 4 x 104 cells/ml in EMEM-10% FCS into 24-well plates were grown to confluence then the medium was replaced with EMEM-1%FCS. After 48 hours in this medium, 50μl aliquotε of mAb or Fab fragment (25μg/ml) and/or TGFα (5ng/ml) were added to triplicate wells and the cells were incubated overnight at 37°C then pulsed for 6 hours with 2μCi/well of 3H-thymidine. The acid insoluble radioactivity incorporated into DNA was determined in a liquid scintillation counter.
Photomicrographs of HN5 tumour cells were taken following treatment for four days with 156nM of ICR62, ICR62 Fab fragment or control antibody 11/160 (27) , and viewed alternatively by phase contrast illumination or by immunofluorescent staining for expression of cytokeratin 10. 5 x 104 HN5 cells were plated onto glass cover slips and placed in 24 well plates containing lml DMEM-2% FCS/well. Following overnight incubation at 37°C, specific or control antibodies (25μg/ml) were added to the cultures and the cells were incubated for a further four days at 37°C. After two washes with PBS, the cells were fixed for 5 minutes in ice-cold methanol then washed by incubation in PBS for 30 minutes. Mouse anti-cytokeratin 10 (RKSE-60, EuroPath Ltd, Cornwall) diluted 1/40 in PBS-0.5% BSA was added and the coverslips were incubated at 4°C for 1 hour. After three washes, bound primary antibody was detected using fluorescein-conjugated sheep anti-mouse Ig (Amersham International Ltd) . The coverslips were mounted in Hydromount:glycerol (1:1) and examined for green fluorescence using a Zeiss Axiovert 100 microscope.
Results
When the Fab preparations of ICR9 and ICR62 were tested for their effects on ligand binding they were found to enhance (ICR9) or inhibit (ICR62) the binding of both 125I-EGF and
125I-TGFα to the receptor on the bladder carcinoma cell line
EJ with similar efficiencies to the bivalent parental IgGs.
At the same concentration, a control rat antibody
(ALN/ii/53) , directed against an unrelated antigen (27) was without effect on the binding of ligand. Scatchard analysis of these data showed that treatment of EJ cells at 4°C with monovalent or bivalent ICR9 promoted the binding of 12BI-EGF to the receptor by increasing the affinity of the receptor for ligand (Figure 5) . The Kd for binding of 125I-EGF was 2.1 x 10β M"1 in medium alone and 7 x 108 M"1 or 1.8 x 109 M"1 in the presence of bivalent or monovalent ICR9 respectively. On the other hand, monovalent and bivalent ICR62 inhibited the binding of EGF completely (Figure 6) . We then compared the monovalent Fab fragments with the parental bivalent antibodies for their effects on the growth of the head and neck carcinoma cell line HN6, which expresses about 1.2 x 10s EGFR/cell (26) . The results illustrated in Figure 7 show that at concentrations above 0.6nM both the Fab fragment and intact ICR9 stimulated the growth of HN6 cells. The Fab fragment of ICR62, likewise, was found (Figure 7) to be as effective as the bivalent mAb at inhibiting the growth in vitro of HN6 cells. Moreover, the monovalent ICR62 inhibited the growth of five other head and neck tumour cell lines (HN5, HSC-1, HSC-2, HSC-4 and Ca9-22) (6,9) which overexpress the EGF receptor (figure 8) . Like the intact ICR62, monovalent Fab fragments of this antibody also inhibited completely the TGFα induced proliferation of quiescent human foreskin fibroblasts (Figure 9) . Furthermore, the Fab of ICR62 was as effective as the bivalent antibody in inducing the differentiation of HN5 cells. The finding that Fab fragments of the rat mAbs ICR9 and ICR62 were as effective as the intact molecule in inducing the respective changes in the function of the EGF receptor was unexpected since other investigators had shown that Fab fragments of murine antibodies were either poorly active or ineffective compared to the intact antibody (3,5,7,8,44,45).
Discussion
The results of our studies (Part 1 above) have shown that the nodules remaining at up to 82 days following the last treatment with antibodies to the EGF receptor consisted largely of necrotic and keratinized areas with few viable cells present. In another study (37) it was reported that treatment of an established human colorectal tumour xenograft with high doses of the mouse anti-EGFR mAb 225
(2mg twice weekly) resulted in complete regression of these tumours by 2-3 weeks (37) . This study also showed that by day 7 most of the cells were necrotic and after 14-21 days most tumour cells had been replaced by connective tissues
(37) . In the present investigation, the presence of keratinized areas was of particular interest and this finding pointed to a previously undescribed effect of treatment with antibodies to the EGFR; namely that prolonged receptor blockade can induce terminal differentiation of the squamous carcinoma cells. We have investigated this function of antibodies to the EGFR by screening the anti-EGFR mAb treated cells for expression of the terminal differentiation markers involucrin, a 92 kD cytoplasmic precursor of cornified envelope (31-33) and cytokeratin 10 expressed during terminal differentiation in squamous epithelia (34-35) . We have shown that during treatment with antibodies to the EGFR the HN5 cells were undergoing terminal differentiation and the majority of the treated cells expressed the differentiation markers involucrin and cytokeratin 10. Furthermore, we also noted that cells expressing these differentiation markers were of larger size as previously shown for cultured human keratinocyteε (32) . The results of our flow cytometric analysiε of HN5 cells following treatment with anti-EGFR mAbs showed that, as would be anticipated for differentiated cells, they were arrested in the G0/G1 phases of the cell cycle. Taken together these results suggeεt, for the firεt time to our knowledge, that antibodieε againεt the EGF receptor which block growth factor-receptor interaction, may inhibit the growth of EGFR overexpreεsing tumours by inducing differentiation. In agreement with our findings, Rodeck and colleagues have shown that growth inhibition of A431 cells by a mouse antibody to the EGFR (mAb 425) , results in a decrease in the percentage of cells in S and G2/M phases of the cell cycle and a increase in the percentage of cells in G0/G1 phases of the cell cycle (20) . A similar mode of action was also suggeεted recently by Bacuε and colleagueε (38) for the effect of growth inhibitory antibodies directed against the external domain of the HER-2/c-erbB-2 receptor, which like EGFR belongε to the type I growth factor receptor family (4) . This study also provided evidence for a relationship between the in vivo antitumour activity of anti-HER-2/c-erbB-2 mAbs and their capacity to induce differentiation of breast cancer cells in vitro (38) .
Two other interesting findings came from the immunohiεtochemical staining of the tumour specimens.
Firstly, it was clear that the increased rate of tumour regression seen during treatment with ICR62 (IgG2b) was due to rapid losε of tumour cells and, in addition, more infiltrating host cells were observed surrounding the tumour foci. As discussed above, although not the most effective inhibitor of growth in vitro, antibody ICR62 was the most effective inducer of the regression of three different human carcinomas grown as xenografts in athymic mice (39) . These results point to a role for host immune effector functions in vivo. Indeed, it is well documented that rat antibodies of the IgG2b isotype, like murine IgG2a and human IgGl, are the most effective at mediating ADCC with Fc-receptor bearing effector cells and in activating the complement cascade (20,40). Secondly, we were surprised to find that in the nodules remaining following treatment of the HN5 tumour with ICR64, cell membranes in the necrotic areas still retained antibody that had been given 77 days earlier. This unexpected finding pointε to the stability of the immune complexes formed and is consistent with the results of experiments in vitro which indicate that the immune complexes formed on binding of these antibodies to HN5 cells are stable and are not rapidly internalised or shed from the cells. The small number of viable cells remaining, which did not stain with the anti-rat Ig reagent, had not lost their expreεsion of the EGFR since they were positive when restained using ICR64 as the first reagent. We conclude that antigenic modulation waε not a εignificant factor in the escape of viable cells from antibody treatment and, providing antibody access waε εatiεfactory, theεe cells might be εuεceptible to further treatment with antibody.
Conclusions. On the basis of our data we conclude that the best antibodies for clinical application will be those which are directed at the correct epitope and are alεo the most effective at inducing terminal differentiation and recruiting and activating host immune effector functions (43) .
The resultε of the further experimentε (Part 2 above) showed that, after four days incubation in the presence of 156nM monovalent or bivalent ICR62 the majority of HN5 cells expresεed the terminal differentiation marker cytokeratin 10 (34) . Control cultures grown in the absence of specific antibody did not express cytokeratin 10, although by four days the cell monolayers were almost confluent. The finding that blockade of the EGF receptor by ICR62 Fab can induce the terminal differentiation of HN5 cells is of some interest and may have clinical application. To our knowledge this is the first report to show that smaller molecules such aε the monovalent Fab fragment of an anti-EGFR antibody can be as effective as bivalent antibody in (a) blocking ligand binding, (b) preventing the growth of tumours overexpressing the EGF receptor, (c) directing terminal differentiation in such ceils. The poεsibility that smaller molecules than intact antibody can be employed to induce these effectε could be significant for clinical application since the rate of extravasation of the smaller molecules should improve uptake into tumour, although clearance from the blood will be increased. The mechanism by which EGF activates the EGF receptor has not yet been resolved and two models (intramolecular or intermolecular activation) have been proposed. The intramolecular model suggests that binding of EGF to the EGF receptor induces a conformational change in the extracellular domain of a receptor monomer which is propagated across the plasma membrane to the cytoplasmic kinase domain leading to its activation (46,49). The intermolecular model (2,3,48) on the other hand, propoεeε that receptor dimerization following ligand binding triggerε phoεphorylation by the cytoplaεmic tyrosine kinase. On the basis of the second model it waε expected that bivalent antibody would block activation by preventing receptor dimerization (3,7,8,44). However, the results of a recent inveεtigation using antibody 13A9 (47) , whose activity haε been shown to take place at a distance from the EGF binding site suggest that this is not the case. In this study, Carraway and Cerione (47) have shown that treatment -.of A431 cells with this antibody prevents EGF receptor aggregation following binding of EGF but does not prevent activation via the receptor as judged by εeveral parameterε including receptor autophoεphorylation, EGF-εtimulated changeε in cytoεolic free [Ca2+] and mitogeneεiε. They provide convincing evidence to suggest that conformational changes in the receptor, not receptor aggregation, is the signal generated following ligand binding. Our results would support this view. With bivalent and monovalent ICR9, it is clear that binding of this antibody causes a marked increase (three to nine-fold) in the affinity of the receptors for EGF. Since these experimentε were carried out at 4°C it is unlikely that this result could be due receptor aggregation. Furthermore, because ICR9 competes with neither the EGFR ligands nor the antibodies that block ligand binding we conclude that it acts at a distance i.e. it induceε a conformational change at the ligand-binding εite. On thiε baεiε we propoεe that, some at least of the antibodies which prevent ligand binding do so by altering the conformation of the receptor to reduce its affinity for ligand. This concept is leant support by the observation that only some of the rat antibodies which block binding of ligand to the EGF receptor are able to diεplace bound ligand i.e εome of the antibodies must act at a diεtance from the ligand binding site. The possibility that scFv or conεtrained peptideε based on the complementarity determining regions of immunoglobulins can be developed for effectively targeting the EGFR on squamouε cell carcinomaε is an exciting prospect especially if such drugs can induce terminal differentiation of the tumour cells. The possibility also existε for developing non-peptide mimetic moleculeε, which mimic the action of theεe binding proteins or peptides, and have a similarly effective interaction with the EGFR. The anti-EGFR antibodies herein can be used to screen for such non- antibody molecules which have a similar effect on tumour cells.
The accompanying sequence listingε εhow within square brackets the complementary determining regions (CDRs) for the heavy and light chains of antibodies ICR62 and ICR64, together with their surrounding framework regions (FRε) . Theεe CDRs can be grafted into the FRs of human antibodies, optionally with retention of selected murine reεidues in the FRs, according to well establiεhed principleε diεcusεed above(see for example, Winter GB-A-2188638, Harris et al WO92/04381 and Queen et al, PNAS (1989), 86:10029-33) to create corresponding humanised antibodies which may be more appropriate for the treatment of humans. Clinical Study Using ICR62 Monoclonal Antibody
For clinical application, it is important to recognise that the EGF receptor is also expressed on some normal human tissueε but the level of expreεsion is much lower than on the corresponding tumour cells (9-11) . However, in our experience tumours which expresε 10s or leεε receptorε are much leεε εenεitive to antibody treatment than are the EGFR overexpressing tumour cells (1,26) . Indeed, Mendelsohn and colleagues in a preclinical study with chimpanzees, have reported that treatment with a total dose of 650mg of antibody produced no toxicity (41) . In addition, in a phaεe I clinical trial where patients with lung carcinoma were treated with doseε of up to 300mg of the mouεe antibody 225 they obεerved no untoward effectε in the patientε (41,42) . mAb ICR62 waε then teεted in a Phaεe I clinical study in patients with cancer of the head and neck (11 pts) or Lung (9 pts) cancers. A majority of the patients in this study had undergone previous treatment (i.e, surgery, radiotherapy, chemotherapy, and/or immunotherapy) . The aims of this clinical study were to (a) monitor patients for any possible signs of toxicity, (b) investigate if therapeutic antibody had localised specifically to tumour cellε in metaεtatic leεionε, (c) determine the level of ICR62 remaining in circulation following treatment and (d) diεcover if the patientε mounted a human anti-rat antibody (HARA) reεponεe.
Materials and Methods
Patient Selection and Treatment
Patientε were conεidered eligible for incluεion in thiε trial who had i) inoperable hiεtologically or cytologically confirmed diagnosis of squamouε cell carcinoma of the lung or head and neck, ii) immunocytochemically proven expreεsion of the EGF receptor, iii) an ECOCG performance status of 0-2, iv) no known history of allergy or atopy, v) no immunological therapy within the previous 4 weekε, vi) no significant abnormalities of renal, hepatic, or bone marrow function ( haemoglobin > lOg/dl, white count > 3xl09/l/ platelet > 120, creatinine < 130, liver enzymes and bilirubin < x2 normal) . Details of tumour grade and the previouε treatments that the patientε had received are εummariεed in Table 1. Patientε were εkin teεted (lOug intradermally) lhr before antibody waε adminiεtered and no patient was found to give an adverse responεe. Antibody in phoεphate buffered εaline pH 7.4 waε given intravenouεly aε a single bolus injection over a period of 30-60 minutes. Groups of three patients were treated with 2.5, 10, 20, or 40mg of ICR62 and a further eight patients were given lOOmg of this antibody. All patients were evaluated for εigns of toxicity. Also, blood samples were taken from these patients before and at intervals after treatment with ICR62 so that the serum could be monitored for the level of mAb ICR62 in circulation and teεted for the preεence of human anti-rat antibodieε (HARA) . In εome of the patients, given antibody doses of 40mg or lOOmg, biopsieε were taken from acceεεible metaεtatic leεionε, 24 hourε following treatment with ICR62 and examined for the localization of ICR62 to the tumour cellε. Preparation of mAb ICR62
All antibody for clinical use waε prepared according to the guidelineε prepared by the CRC-MRC Joint Committee. Hybridoma cellε were grown in Dulbecco's modified Eagle's medium (DMEM) containing 3% or 5% fetal calf serum of North American origin and antibiotics as described previously (27) , in either in a Verax Type 1 Bioreactor or as bulk cultures in roller bottles. Supernatants were harveεted under aseptic conditions and then precipitated with
(NH4)2S04 at 45% εaturation. Uεing autoclaved reagents, column packings and containerε, the precipitates were disεolved in water and dialyεed againεt 0.0175M phoεphate buffer pH 6.6. After centrifugation in a Beckman 45Ti rotor at 30,000g to remove insoluble material, the dialysate was fractionated by passage through a column of Whatman DE52 cellulose equilibrated with and eluted with 0.0175M phosphate buffer pH 6.6. The flow through fractions containing the purified (>95% mAb) ICR62 were bulked and dialysed against five changes of sterile phosphate buffered saline (PBS) . After filter sterilisation the preparation was aliquoted, frozen and stored at -20°C until use. Determination of the level of ICR62 in Circulation
The amount of free mAb ICR62 preεent in εerum waε determined by its ability to inhibit the binding of EGF or TGF to the bladder carcinoma cell line EJ as described previously (27) . Doubling dilutions of serum (50μl) were mixed with an equal volume of 125I-EGF (4xl04cpm) or 125i- TGF (4xl04cpm) . Standards containing known concentrations of ICR62 were set up in the same way. Aliquots of 90μl of each mixture were then transfered to monolayers of EJ cells grown to confluency in 96 well plates. After incubation for one hour on ice the cells were washed three times, then lysed in 1M NaOH containing 1% εarkoεyl and the bound radioactivity waε determined in a Hydragamma spectrometer (Oakfield Instrumentε Ltd., Oxford).
Determination of Human Anti-Rat (HARA) Response
Polyvinyl chloride 96-well plates (Dynatech Labs, Virginina) , were coated with rat antibody by incubation overnight at 4°C with 50μl/well of a stock sloution
(10μg/5ml of PBS) of ICR62, ICR62 Fab, or ICR62 scFv. The plates were washed three timeε with PBS containing 0.5% BSA and then incubated for 2 hourε with 200μl/well of PBS-0.5%
BSA to block the remaining εiteε. After a further three waεheε with PBS containing 0.5% BSA, doubling dilutionε of the patientε sera made in PBS-0.5% BSA were added in duplicate to the wells and the plates were incubated for l hour at ambient temperature. After washing the plates three times with PBS-0.5% BSA, human antibodies bound to ICR62 or its fragmentε were detected by the addition of 125I-labelled rabbit anti-human F(ab')2. After incubation for 1 hour at ambient temperature, the plateε were waεhed three ti eε with PBS-0.5% BSA and then cut into individual wells and the bound radioactivity determined in a Hydragamma counter.
Immunohistochemistry
All immunohistochemical εtudies were performed by the indirect method using sheep antibodieε to rat F(ab')2 conjugated to horεeradish peroxidase (Amersham International) .
To determine expression of the EGFR, tumour biopsies were snap frozen in liquid nitrogen then mounted in OCT medium and sections of 5μm thicknesε cut. One εection waε stained with Haematoxylin & Eosin (H&E) to determine the nature of the tumour εample. A second sample was fixed in acetone at 4°C for 10 minutes, then after waεhing briefly in PBS the εection waε incubated with mAb ICR62 (lOOμg/ml, for 1 hour. Following washing in PBS for 5 minutes, the sections were incubated with a 1:100 dilution of sheep anti-rat F(ab')2 conjugated to horse radish peroxidase (Amersham) for 45 minutes. Peroxidase staining was demonstrated by incubating the sectionε for 10 minuteε in a εolution containing 0.05% diaminobenzidine (Sigma), 0.1% hydrogen peroxide (Merck) and 0.07% imidazole (Merck) . After waεhing in running tap water for 5 minuteε, the sections were counterstained in Mayer'ε Haematoxylin (HD Supplierε) for 30 seconds. Finally the sectionε were dehydrated, cleared and mounted.
To monitor the localiεation of ICR62 to tumour cellε in patientε that were given doses of 40mg or lOOmg of antibody, biopsieε were taken from metastatic sites, 24 hours after the antibody was administered, then frozen sections were cut and stained with sheep anti-rat antibody alone. To determine the proportion of cells that had bound therapeutic antibody, serial sectionε taken from the εame biopεies were stained first with ICR62 followed by the peroxidase conjugated sheep anti rat F(ab')2 so that all EGFR expressing cells were stained.
Results. Effect of treatment on patients
Twenty patients with squamous cell carcinoma of the head and neck or lung whose tumourε were found to overexpress the EGF receptor were recruited into this dose escalation trial to assess the toxicity of the rat mAb ICR62 (Table 1) . All had extensive diseaεe and, with the exception of four patients (εee Table 1) , had received previous treatment (ε) for their diεeaεe e.g. εurgery, radiotherapy and/or chemotherapy (Table 1) .
Patientε were admitted to hoεpital on the day before the adminiεtration of antibody and their biochemical and haematological parameters were monitored. Following intravenouε injection of the antibody some of the patients exhibited mild rigors and fever or hypotension (Table 1) . The symptomε which were not related to the doεe of antibody adminiεtered were readily controlled. In no caεe were any εevere toxicitieε observed. The patients were released from hospital 24 hours after the injection of antibody and they were seen at weekly intervals for up to six weeks. None of the patients reported any untoward effects of their treatment during the follow-up period.
Blood levels of ICR62 We have investigated if mAb ICR62 could be detected in the serum of patients given different doses of this antibody by monitoring the inhibition of binding of EGF or TGF to the EGFR by εera taken at intervalε following treatment. We have been unable to detect any free antibody in the εerum, taken at 4 hourε or 24 hourε poεt-treatment, of patients that were given 20mg or less of ICR62 (Figure la) . However, significant amountε of circulating ICR62 could be detected, in the blood of patientε given doseε of 40mg or lOOmg of ICR62 (Figure lb & lc) . In addition, the level of ICR62 remaining in circulation waε found to be higheεt in patientε recieving lOOmg of ICR62. In one patient, about half of the antibody adminiεtered waε in circulation on day 3 but no free mAb could be detected in the blood at 7 days post ICR62 treatment.
Injected ICR62 binds to the EGFR on tumour cell membranes
Biopsieε were taken of metaεtatic leεions from six patientε, 24 hours after treatment of the patients with 40mg or lOOmg of ICR62. Frozen εections were examined for the presence of cell bound antibody by staining directly with a peroxidase-conjugated second antibody reagent. Two of the biopsieε were found to conεist largely of necrotic material and were discarded but four yielded well defined regions containing infiltrating tumour. The sections illustrated in figure 2a show that 24 hours after treatment of two patients with 40mg of ICR62, the antibody had localized to the membranes of tumour cells in the metastatic sites and the proliferating cells at the periphery of the tumour were strongly stained. When a sequential section was stained with ICR62 prior to the addition of the sheep anti-rat reagent, it was found that cells at the interior of the tumour which alεo expreεsed the EGFR had not bound the therapeutic antibody administered 24 hours earlier (figure 2b) . However, when frozen sections of biopsies obtained from metastases of two patients treated with lOOmg of ICR62 were examined, it was clear that the mAb had penetrated further into the metaεtatic leεionε (Figureε 3a & 3b) . Again, very good membrane staining of the proliferating cells at the tumour periphery was observed. Development of human antibodies to ICR62
We have investigated the immunogenicity of mAb ICR62 in these patients by determining if human anti-rat antibodies (HARA) were present in the serum of patientε given different doses of ICR62. Also, we have investigated if the human anti-rat reεponεe included anti-idiotypic antibodies by determining if the antibodies in the patients serum bound to scFv fragments of ICR62. Of the twenty patients treated with ICR62, human anti-rat antibodies were detected in the blood of only four patients (numbers 9, 10, 16 and 19 see Table 1) .
Of these only two patients given 20mg (No 9) or 40mg (No 11) produced anti-idiotypic antibodies which bound to scFv
ICR62 ( Table 1, Figure 4) . Sera from two out of the eight patientε treated with lOOmg of ICR62 (patients 16 and 19) contained antibodies directed against determinants on the constant region since they bound to the Fab and intact antibody but not to the ICR62 scFv (Table 1, Figure 5) . In one patient (No 12) , the results obtained with the serum taken before treatment indicated that antibodies which bound to rat IgG were present in the sera before ICR62 was administered but testε were not done to determine if binding waε εpecific or due to the presence of autoantibodies such as rheumatoid factor.
Discussion. Overexpression of the EGFR accompanied by production of the EGF family of ligandε haε been found to occur in a wide range of human malignancies and this phenomenon haε been correlated with a poorer prognosis in these patients. During the past fourteen years a number of mouse monoclonal antibodies have been raised against epitopes on the external domain of the human EGFR and these have been used not only to inveεtigate growth factor-receptor interaction and the mechanism(s) of activation of the EGF receptor syεtem but alεo for diagnostic and therapeutic applications in cancer. Several of the mouse antibodies have undergone clinical evaluation in Phase I and Phase II εtudies in patients with head and neck, lung or brain cancers including mAb EGFR1 (52,53), mAbs 225 and 528 (42,54), mAb 425 (EMD 55900 E Merk, 55-59) and mAb RG83852 (60) . The aim of these studieε, like the one preεented here, waε to determine whether treatment of cancer patientε with anti- EGFR mAbs produced life threatening toxicities by binding to the EGFR expreεsed by normal tisεueε including liver and εkin. The reεultε of theεe εtudieε have εhown that mouse antibodies to the EGFR can be given safely to patients without toxicity. For example, Divigi and colleagues have treated patients with advanced εquamouε cell carcinoma of the lung with εingle doεeε of up to 300mg of mAb 225, including 4mg of indium Ill-labeled 225, without any sign of toxicity (42) . Furthermore, with doses of 40mg or greater they were able to image presumed sites of metastaεiε greater or equal to 1cm in diameter (42) .
We selected mAb ICR62 for a phase I clinical study since it was the most effective of a large number of rat mAbs we had made againεt the human EGFR, at inducing the regreεεion of xenograftε of head and neck, vulva and breast carcinomas grown in athymic mice (39,50,51) . The results of this Phase I clinical study has indicated that mAb ICR62 can be given safely, at doses up to lOOmg, to cancer patients without any life threatening toxicities. This finding is in agreement with the reεultε of studies with mouse antibodies to the EGFR described above. Furthermore, in patients that had been given doseε of 40 or lOOmg of ICR62, significant amounts of therapeutic mAb were detected in the blood of these patients at 4 and 24 hourε poεt ICR62 treatment. Moreover, in these patients, good localization of ICR62 was observed in metastatic lesionε at 24 hourε following treatment and penetration of antibody waε greater in the tumourε of patientε treated with lOOmg of the mAb. Importantly, the moεt acceεεible cells, i.e. those nearest the blood supply, are likely to be the most actively dividing cells and these were the most strongly stained. It iε the proliferation of these cells which muεt be arreεted. The maintainance of receptor blockade may require repeated treatment with antibody. Certainly, our experience uεing the xenograft model (39,50,51) pointε to the need to maintain εufficiently high blood levels for long enough to a) block EGFR function, b) recruit to the tumour and activate host effector cells and c) induce terminal differentiation. The data on the blood half-life of ICR62 obtained in this investigation εuggeεt that twice weekly doses of lOOmg may be sufficient to maintain a high enough level of this antibody for therapeutic activity. In the present investigation we were able to biopsy metastatic sites at only a single timepoint so we have no information concerning the stability of the antibody at the tumour cell surface or of the effects of treatment on the recruitment and activation of host immune effector cells. When sera were tested for antibodies to rat immunoglobulin, we found that only four out of the twenty patients had responded following a single dose of mAb ICR62. Of theεe, only two were directed againεt the idiotype of ICR62. These results suggest that mAb ICR62 was not as immunogenic as the mouse antibodies to the EGFR that have been used previously in clinical studieε. For example, Divigi and colleagueε found all 19 lung cancer patientε treated with a εingle doεe of 1 to 300mg of mAb 225 developed human anti-mouεe antibodies (42) . Stasieki and colleagues have also found that a single infusion or multiple infusions at monthly intervals of mAb EMD 55900 in glioma patients elicited human anti-mouεe antibodieε (57) . On the other hand, theεe authors reported that following multiple infuεionε of glioma patientε with mAb EMD 55900 at εhorter intervalε (three timeε/week, during 4 weekε or longer) , human anti-mouεe antibodieε were not detectable in the εerum of these patients (57) . The immunogenicity of anti- EGFR mAbs may however, be reduced by either production of chimearic or humanized version of the antibodies or by uεing different antibodies to the EGFR for the second and third treatment.
In summary, the results of this Phase I dose escalation study has indicated that the rat mAb ICR62, which acts as an EGF and TGF antagonist, a) can be adminstered safely in patients with squamouε cell carcinoma, b) localizeε efficently to metaεtatic sites in patients with squamous cell carcinoma, and c) may therefore be useful in the treatment of a significant number of cancer patientε whoεe tumourε overexpreεε the EGF receptor. From the reεultε of our preclinical εtudieε in athymic mice, we have noted that to achieve tumour deεtruction repeated adminεtration of EGFR mAbε may be required. For thiε reaεon, a phase II clinical study is planned using multiple doεeε of mAb ICR62.
TABLE 1
Figure imgf000028_0001
References
1. Modjtahedi, H. and Dean C. The receptor for EGF and its ligands: Expression, prognostic value and target for therapy in cancer (Review) . Int. J. Oncol.,4,
1994, (in press) .
2. Ullrich,A. and Schlessinger,J. Cell. 61, 203-212
(1990) .
3. Spaargaren,M. , Defize, L.H.K. , Boonstra,J. and de Laat,S.W. J. Biol. Chem., 266, 1733-1739 (1991) .
4. Prigent,S.A. and Lemoine,N.R. The type 1 EGFR-related family of growth factor receptors and their ligands . Progress in Growth Factor Research, 4: 1-24 1992.
5. Aboud-Pira , E. , Hurwitz,E., Pirak,M.E. , Bellot,F., Schlessinger,J. and Sela,M. J.Natl .Cancer. Inst . , 80,
1605-1611 (1988) .
6. Kamata, N., Kazuhiro, C, Rikimaru, K., Horikoshi, M., Enomoto, S. and Kuroki, T. Cancer Res., 46, 1648-1653 (1986) . 7. Sato,J.D., Kawamoto,T., Le,A.D., Mendelsohn,J.
Polikoff,J. and Sato,J.H. Mol.Biol., Med. 1, 511-514
(1983) . 8. Fan,Z., Masui,H., Altas,I. and Mendelsohn,J. Cancer
Res. 53, 4322-4328 (1993) . 9. Cowley,G., Smith,J.A., Gusterson,B. , Hendler,F., and
Ozanne,B. The amount of EGF receptor is elevated on squamous cell carcinomas. Cancer Cells, 1: 5-10, 1984.
10. Hendler,F.J. and Ozanne B. . Human squamous cell lung cancers express increased epidermal growth factor receptors. J. Clin. Invest., 74: 647-651, 1984.
11. Ozanne,B., Richards, C.S . , Hendler,F., Burns,D. and Gusterson,B. Overexpression of the EGF receptor is a hallmark of squamous cell carcinomas. J.Pathol., 149: 9-14, 1986. 12. Gullick, .J. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers . British Medical Bulletin, Vol 47: No.l 87-98 1991.
13. Harris,AL, Nicholson, S, Sainsbury,R, Wright, C and Farndon,J.R. Epidermal growth factor receptor and other oncogenes as prognostic markers. J. Natl.
Cancer Inst. Monogr. 11: 181-87, 1992.
14. Sporn,M.B. and Roberts,A.B. Autocrine growth factors and cancers. Nature, 313: 745-747, 1985.
15. Di Marco, E., Pierce, J. H., Fleming, T. P., Kraus, M. H., Molloy, C. J. , Aaronson, S. A. and DiFore, P. P.
Autocrine interaction between TGFα and the EGF- receptor: quantitative requirements for induction of the malignant phenotype. Oncogene, 4: 831-838, 1989.
16. Yoshida,K., Kyo,E., Tsuda,T., Tsujino,T., Ito,M. and Tahara,E. EGF and TGFα, the ligands of hyperproduced
EGFR in human esophageal carcinoma cells act as' a autocrine growth factor. Int.J.Cancer 45: 131-135, 1990.
17. Morishigie, K. I . , Kurachi,H., Amemiya, K.Fujita,Y., Yamamoto,T., Miyake,A. and Tanizawa,0. Evidence for the involvement of TGFα and EGFR autocrine mechanism in primary human ovarian cancers in vitro. Cancer Res., 51: 5322-5328, 1991.
18. Masui,H., Kawamoto,T. Sato,J.D., Wolf,B., Sato,G. and Mendelsohn,J. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Research. 44: 1002-1007, 1984.
19. Van de Vijvert,M. , Kumar,R. and Mendelsohn,J. Ligand- induced activation of A431 cell epidermal growth factor receptors occurs primarily by an autocrine pathway that acts upon receptors on the surface rather than intracellularly. J. Biol. Chem., 266: 7503-7508, 1991.
20. Rodeck,U., Herlyn,M., Herlyn,D., Molthoff,C, Atkinson,B., Varello,M., Steplewski,Z. and
Koprowski,H. Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: Immunological mediated and effector cell-independent effects. Cancer Research. 47: 3692-3696, 1987. 21. Imanishi,K., Yamaguchi,K. , Kuranami,M., Kyo,E., Hozumi,T. and Abe,K. Inhibition of growth of human lung adenocarcinoma cell lines by anti-transforming growth factor-α monoclonal antibody. J. Natl. Cancer Inst., 81: 220-223, 1989. 22. Fendly,B.M., Winget,M., Hudziak,R.M. , Lipari,M.T. , Napier, .A. and Ullrich,A. Characterization of murine monoclonal antibodieε reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res., 50:, 1550-1558, 1990. 23. Sato,H. and Sato,J.D. Growth factor receptor monoclonal antibodies and cancer immunotherapy. J. Nat. Cancer Inst. 81: No21 1600-1601, 1989.
24. Mendelsohn,J. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. J. Natl. Cancer Inst. Monogr. 13: 125-131,
1992.
25. Modjtahedi,H. , Styles,J., Box,G., Eccles,S., Gusterson,B. , and Dean,C. Antitumour activity of rat Mabs to the human receptor for EGF. In, Mutant Oncogenes: Targets for Therapy? Eds. Epenetos,A.A. and
Lemonie,N.R. Chapman & Hall, London pp35-47, 1993.
26. Modjtahedi,H. , Styles,J.M., and Dean,C.J. The human EFG receptor as a target for cancer therapy : six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Br. J. Cancer, 67: 247-253, 1993.
27. Dean,C.J., Styles,J.M., Gyure,L.A., Peppard,J., Hobbs,S.M., Jackson,E., and Hall,J.G. The production of hybridomas from the gut associated lymphoid tissue of tumour bearing rats. I. Mesenteric nodes as a source of IgG producing cells. Clin.exp.Immunol. , 57: 358-364, 1984.
28. Hudson, D. L., Weiland, K. L., Dooley, T. P., Simon, M. and Watt, F. M. Characterisation of eight monoclonal antibodies to involucrin. Hybridoma, 11: 367-379, 1992.
29. Modjtahedi, H., Eccles, S. Box, G, Styles, J. and Dean C.J. Antitumour activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor. Cell BioPhysics 21/22: 1993 (in press). 30. Ormerod,M.G. Analysis of DNA. In, Flow Cytometry, Ed M. G. Ormerod Oxford University Press, New York, 69- 87, 1990.
31. Banks-Schlegel, S. and Green, H. Involucrin synthesis and tissue assembly by keratinocytes in natural and cultured human epithelia. J. Cell Biol., 90: 732-737,
1981.
32. Watt, F. M. and Green, H. Involucrin synthesis is correlated with cell size in human epidermal cultures. J. Cell Biol., 90: 738-742, 1981. 33. Walts, A. E. and Said, J. W. Involucrin, a marker of squamous and urothelial differentiation. An immunohistochemical study on its distribution in normal and neoplastic tissues. J. Path., 145: 329-340, 1985. 34. Moll, R., Franke, W. W., Schiller, D. L., Geiger, B. and Krepler, R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell, 31: 11-24, 1982.
35. Lane, E. B. and Alexander, C. M. Use of keratin antibodies in tumor diagnosis. Cancer Biology, 1: 165-
179, 1990.
36. Leger, O.J.P. and Dean, C.J. Mol. Immunol. 28, 673- 680, (1991) .
37. Tachikawa, T., Boman, B., Mendelsohn,J. , and Masui, H., Tumour cytotoxity by anti-epidermal growth factor receptor EGFR monoclonal antibody mAb. Proc.Amer.Assoc. Cancer Res.33:345, 1992.
38. Bacus,S.S., Stancovski,H. , Huberman,E., Chin,D., Hurwitz,E., Mills,G.B., Ullrich,A. , Sela,M. and Yarden,Y. Tumor-inhibitory monoclonal antibodies to the HER-2/neu receptor induce differentiation of human breast cancer cells, 52: 2580-2589, 1992.
39. Modjtahedi, H., Eccles, S.A., Box, G., Style, J., and Dean C, Immunotherapy of human human tumor xenografts overexpressing the EGF receptor with rat antibodies that block growth factor receptor interaction. Br.J.Cancer 67: 254-261, 1993.
40. Bruggemann, M., Teale, C, Clark M., Bindon C, and Waldmann H., A matched set of rat/mouse chimeric antibodies. J.Immunol. 142:3145-3150, 1989.
41. Mendelsohn, J., The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Seminars in Cancer Biology 1:339-344, 1990. 42. Divigi, C.R., Welt, S., Kris, M. , Real, F.X., Yeh, S.D.J., Gralla,R., Merchant, B., Schweighart, S., Unger, M., Larson, S.M., and Mendelsohn, J. Phase I and Imaging Trial of Indium Ill-Labeled Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 in patients with Squamous Cell Lung Carcinoma. J. Natl.
Cancer Inst. 83:97-104, 1991. 43. Pierce, G.B., and Speers, W.C, Tumours as Caricatures of the Process of Tissue Renewal: Prospects for Therapy by Directing Differentiation. Cancer Res. 48:1996-2004, 1988. 44. Schreiber,A.B. , Libermann,T.A. , Lax, I., Yarden,Y. and Schlessinger,J. J. Biol. Chem. 258, 846-853 (1983) .
45. Fernandez-Pol,J.A. J.Biol.Chem. , 260, No 8, 5003-5011 (1985) .
46. Koland, J.G and Cerione, R.A. J.Biol .Chem. , 263,2230- 2237 (1988)
47. Carraway, K.L., and Cerione R.A. J.Biol .Chem. , 268, 23860-23867 (1993)
48. Yarden,Y., and Schlessinger,J. Biochemistry 26, 1434- 1442 (1987) . 49. Weber, W., Bertics, P.J., and Gill G.N. J.Biol .Chem. , 259, 14631-14636 (1984) . 50. Dean CJ, Modjtahedi H, Eccles S, et al : Immunotherapy with antibodies to the EGF receptor. Int J Cancer 8:103-107 1994. 51. Modjtahedi H, Eccles S, Sandle J, et al: Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor. Cancer Research. 54:1695-1701, 1994. 52. Soo KC, Ward M, Roberts KR, et al. , Radioimmunoscintigraphy of squamous carcinomas of the head and neck. Head and Neck Surgery 9:349-352, 1987.
53. Kalofonos HP, Pawlikowska TR, Hemingway A, et al: Antibody guided diagnosis and therapy of brain gliomas using radiolabeled monoclonal antibodies against epidermal growth factor receptor and placental alkaline phosphatase. J Nucl Med, 30:1636-1645, 1989.
54. Baselga J, Scott A, Pfister D, et al: Comparative pharmacology in Phase I and imaging trials utilizing anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MAbs) labeled with 1311 or 111IN. Proc Annu Meet Am Soc Clin Oncol, 12:A368, 1993.
55. Brady LW, Miyamoto C, Woo DV, et al : Malignant astrocytomas treated with iodine-125 labelled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiation Oncology Biol Phys, 22:225-230, 1991.
56. Magdelenat H, Delattre JY, Mady E, et al : A phase I study of the anti-EGFR monoclonal antibody 425 in patients with malignant gliomas. J Tumor Marker Oncol 6(4) :60, 1991.
57. Stasiecki P, Kemshead JT, Westphal M, et al : The development of HAMA in glioma patients can be suppressed by administration of murine MAb in short time intervals. Proc Annu Meet Am Assoc Cancer Res, 34:A2835,1993.
58. Bilzer T, Stassiecki P, Vega F, et al : Immunotherapy of malignant gliomas with the anti-EGFR monoclonal antibody. Proc Annu Meet Am Assoc Cancer Res,
34:A2877, 1993. 59. Dadparvar S, Krishna L, Miyamoto C, Brady LW, Brown SJ, Bender H, Slizofski WJ, Eshleman J, Chevres A, Woo DV: Indium-lll-labeled anti-EGFr-425 scintigraphy in the detection of malignant gliomas. Cancer Suppl 73:884-889, 1994.
60. Shin DM, Perez-Soler R, Donato NJ, et al: Tumor epidermal growth factor receptor (EGFR) saturation and proliferating cell nuclear antigen (PCNA) expression in patients treated with anti-EGFR monoclonal antibody (MoAb) RG83852 (in Phase I clinical study) . Proc Annu
Meet Am Soc Clin Oncol, 12:A940, 1993.
Sequence Listings ICR62
ICR62VH
30 60
ATG GGA TGG ATC TGT ATC ATC TTT CTT GTG GCA ACA GCT ACA GGT GGC CAC TCC CAG GTC Met Gly Trp He Cys He He Phe Leu Val Ala Thr Ala Thr Gly Gly His Ser Gin Val
90 120
AAC CTA CTG CAG TCT GGG GCT GCA CTG GTG AAG CCT GGG GCC TCT GTG AAG TTG TCT TGC Asn Leu Leu Gin Ser Gly Ala Ala Leu Val Lys Pro Gly Ala Ser Val Lys Leu Ser Cys
150 180
AAA GGT TCT GGT TTT ACA TTC ACT|GAC TAC AAG ATA CAC : TGG GTG AAG CAG AGT CAT GGA Lys Gly Ser Gly Phe Thr Phe Thr Asp Tyr Lys He His Trp Val Lys Gin Ser His Gly
210 240
AAG AGC CTT GAG TGG ATT GGG TATTTTAATCCTAACAGTGGTTATAGTACCTACAATGAA Lys Ser Leu Glu Trp He Gly Tyr Phe Asn Pro Asn Ser Gly Tyr Ser Thr Tyr Asn Glu
270 300
AAG TTC AAG AGC] AAG GCC ACA TTG ACT GCA GAC AAA TCC ACC GAT ACA GCC TAT ATG GAG
Lys Phe Lys Ser Lys Ala Thr Leu Thr Ala Asp Lys Ser Thr Asp Thr Ala Tyr Met Glu
330 360
CTT ACC AGT CTG ACA TCT GAG GAC TCT GCA ACC TAT TAC TGT ACA AGA CTA TCC CCA GGG Leu Thr Ser Leu Thr Ser Glu Asp Ser Ala Thr Tyr Tyr Cys Thr Arg Leu Ser Pro Gly
390 420
GGT TAC TAT GTT ATG GAT GCC TGG GGT CAA GGA GCT TCA GTC ACT GTC TCC TCA GCC CAA Gly Tyr Tyr Val Met Asp Ala Trp Gly Gin Gly Ala Ser Val Thr Val Ser Ser Ala Gin 450
ACA ACA GCC CCA TCT GTC TAT CCA CTG GCT CCT GGA
Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Gly ICR62VK
30 60
ATG ATG GCT CCA GTC CAG CTC TTA GGG CTG CTG CTG ATT TGG CTC CCA GCC ATG AGA TGT Met Met Ala Pro Val Gin Leu Leu Gly Leu Leu Leu He Trp Leu Pro Ala Met Arg Cys
90 120
GAC ATC CAG ATG ACC CAG TCT CCT TCA TTC CTG TCT GCA TCT GTG GGA GAC AGA GTC ACT Asp He Gin Met Thr Gin Ser Pro Ser Phe Leu Ser Ala Ser Val Gly Asp Arg Val Thr
150 180
ATC AAC TGC AAA GCA AGT CAG AAT ATT AAC AAT TAC TTA AAC TGG TAT CAG CAA AAG CTT He Asn Cys Lys Ala Ser Gin Asn He Asn Asn Tyr Leu Asn Trp Tyr Gin Gin Lys Leu
210 240
GGA GAA GCT CCC AAA CGC CTG ATA TAT : AAT ACA AAC AAT TTG CAA ACA GGC ATC CCA TCA Gly Glu Ala Pro Lys Arg Leu He Tyr Asn Thr Asn Asn Leu Gin Thr Gly He Pro Ser
270 300
AGG TTC AGT GGC AGT GGA TCT GGT ACA GAT TAC ACA CTC ACC ATC AGC AGC CTG CAG CCT Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr He Ser Ser Leu Gin Pro
330 360
GAA GAT TTT GCC ACA TAT TTC TGC ! TTG CAG CAT AAT AGT TTT CCC ACG TTT GGA GCT GGG Glu Asp Phe Ala Thr Tyr Phe Cys Leu Gin His Asn Ser Phe Pro Thr Phe Gly Ala Gly 390 420
ACC AAG CTG GAA CTG AAA CGG GCT GAT GCT GCA CCA ACT GTA TCT ATC TTC CCA CCA TCC Thr Lys Leu Glu Leu Lys Arg Ala Asp Ala Ala Pro Thr Val Ser He Phe Pro Pro Ser
AAA TCG
Lys Ser Sequence Listings ICR64
ICR64VΗ
30 60
ATG AAG TTG TTG CTA AAC TGG GTT TTT CTA GTA ACA CTT TTA AAT GGT ATT CAG TGT GAG Met Lys Leu Leu Leu Asn Trp Val Phe Leu Val Thr Leu Leu Asn Gly He Gin Cys Glu
90 120
GTG AAG CTG GTA GAA TAT GGA GGA GGT TTG GTG CAG CCT GGG CTT CTC TCA GAC CTC TCC Val Lys Leu Val Glu Tyr Gly Gly Gly Leu Val Gin Pro Gly Leu Leu Ser Asp Leu Ser
150 180
TGC GAA GCT TCT GGA TTC ATG TTC AGT GAT TTC TTC ATG GAG TGG ATC CGA CAG GCT CCA Cys Glu Ala Ser Gly Phe Met Phe Ser Asp Phe Phe Met Glu Trp He Arg Gin Ala Pro 210 240
GGG AAA GGA CTG GAG TGG ATT GCA GCA AGT AGA AAC AAA GCT AAC GAT TAT TCA GCA GTG Gly Lys Gly Leu Glu Trp He Ala Ala Ser Arg Asn Lys Ala Asn Asp Tyr Ser Ala Val 270 300
TAC AGT GCA TCT GTG AAG GAC CGA TTC ACC ATC TCA AGG GAT TCT CAC AAA AGC ATC CTC Tyr Ser Ala Ser Val Lys Asp Arg Phe Thr He Ser Arg Asp Ser His Lys Ser He Leu 330 360
TAT CTT CAG ATG AAC ACA CTC AAA CCT GAG GAT ACT GCC ATT TAT TAC TGT GCA AGA GAT Tyr Leu Gin Met Asn Thr Leu Lys Pro Glu Asp Thr Ala He Tyr Tyr Cys Ala Arg Asp
390 420
TAT TAC CAA AGT GGC TTG TTT GAT TAC TGG GGC CAA GGA GTC ATG GTC ACA GTC TCC TCA Tyr Tyr Gin Ser Gly Leu Phe Asp Tyr Trp Gly Gin Gly Val Met Val Thr Val Ser Ser ICR64VK
30 60
ATG GGT GTG CCC ACT CAG CTC CTG GGG TTG TTG CTG CTG TGG ATA ACA GAT AGA ATA TGT Met Gly Val Pro Thr Gin Leu Leu Gly Leu Leu Leu Leu Trp He Thr Asp Arg He Cys
90 120
GAC ATC CAG ATG ACA CAG TCT CCA GCT TCC CTG TCT GCA TCT CTG GGA GAA ACT GTC ACC Asp He Gin Met Thr Gin Ser Pro Ala Ser Leu Ser Ala Ser Leu Gly Glu Thr Val Thr
150 180
ATC GAA TGT CTA GTA AGT GAA GAC ATT TAC AGT AAT TTA GCG TGG TAT CAG CAG AAG CCA He Glu Cys Leu Val Ser Glu Asp He Tyr Ser Asn Leu Ala Trp Tyr Gin Gin Lys Pro
210 240
GGG AAA TCT CCT CAG CTC CTG ATC TAT GAT GCA AGT AGC TTG CAA GAT GGG GTC CCA TCA Gly Lys Ser Pro Gin Leu Leu He Tyr Asp Ala Ser Ser Leu Gin Asp Gly Val Pro Ser 270 300
CGG TTC AGT GGC AGT GAA TCT GGC ACA CAG TAT TCT CTC GAG ATC AAC AGC CTG CAA TCT Arg Phe Ser Gly Ser Glu Ser Gly Thr Gin Tyr Ser Leu Glu He Asn Ser Leu Gin Ser
330 360
GAA GAT GCC GCG ACT TAT TTC TGT CAA CAG CAT CAT GAT TAT CCT CGG ACG TTC GGT GGA Glu Asp Ala Ala Thr Tyr Phe Cys Gin Gin His His Asp Tyr Pro Arg Thr Phe Gly Gly
GGC ACC AAG CTG GAA TTG AAA Gly Thr Lys Leu Glu Leu Lys

Claims

1. Antibodies to EGF receptor, or fragments thereof, for therapeutic use.
2. Antibodies according to claim 1 wherein the antibodies are antibodies ICR62, ICR64 or ICR16, or fragments thereof.
3. A mutant, derivative, or functional equivalent of the antibodies according to claim l or claim 2.
4. Antibodies according to claim 3 wherein the antibodies are humanised, having framework regions based on or derived from a human antibody and having complementary determining regions (CDRs) derived from a non-human antibody.
5. Antibodies according to claim 4 wherein the antibody has complementary determining regions (CDRs) derived from the ICR62VH, ICR62VK, ICR64VH or ICR64VK sequences shown in the accompanying sequence listing.
6. A fragment of an antibody to EGF receptor having the property of inducing terminal differentiation in tumour cells.
7. A fragment according to claim 6 wherein the fragment is a Fab fragment.
8. Use of the antibodies or fragments of antibodies as defined in any one of claims 1 to 7 in the preparation of a medicament for inducing terminal differentiation in tumour cells.
9. The use according to claim 8 wherein the cells are characterised by over-expressing EGF receptor.
10. The use according to claim 8 or claim 9 wherein the tumour cells are bladder, brain, head, neck, pancreas, lung, breast, or ovary tumour cells.
11. Isolated nucleic acid encoding an antibody or fragment of an antibody according to any one of claims 1 to 7.
12. An expression vector comprising the DNA of claim 11, the DNA being operably linked to control sequences for expressing the DNA.
13. Host cells transformed by the expression vector of claim 12.
14. A pharmaceutical composition comprising one or more of the antibodies or fragments of antibodies as defined in any one of claim 1 to 7.
15. A pharmaceutical composition according to claim 14 comprising from 1 to 300mg of the antibodies.
16. A pharmaceutical composition according to claim 14 or claim 15 wherein the antibodies or fragments of antibodies are conjugated to a cytotoxic compound, drug or toxin, or a label.
17. A functional mimetic of an antibody or fragment of an antibody as defined in any one of claims 1 to 7.
18. The use of an antibody or fragment of an antibody as defined in any one of claims 1 to 7 for the design or synthesis of peptide or non-peptide compounds which are functional mimetics of the antibody
PCT/GB1995/000118 1994-01-21 1995-01-23 Antibodies to egf receptor and their antitumour effect WO1995020045A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP95906400A EP0737251A1 (en) 1994-01-21 1995-01-23 Antibodies to egf receptor and their antitumour effect
AU14601/95A AU691865B2 (en) 1994-01-21 1995-01-23 Antibodies to egf receptor and their antitumour effect
JP7519421A JPH09510605A (en) 1994-01-21 1995-01-23 Antibody against EGF receptor and antitumor effect thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9401182.2 1994-01-21
GB9401182A GB9401182D0 (en) 1994-01-21 1994-01-21 Antibodies to EGF receptor and their antitumour effect

Publications (1)

Publication Number Publication Date
WO1995020045A1 true WO1995020045A1 (en) 1995-07-27

Family

ID=10749157

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/000118 WO1995020045A1 (en) 1994-01-21 1995-01-23 Antibodies to egf receptor and their antitumour effect

Country Status (6)

Country Link
EP (1) EP0737251A1 (en)
JP (1) JPH09510605A (en)
AU (1) AU691865B2 (en)
CA (1) CA2180834A1 (en)
GB (1) GB9401182D0 (en)
WO (1) WO1995020045A1 (en)

Cited By (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0712863B1 (en) * 1994-11-18 2002-02-27 Centro de Inmunologia Molecular Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use
EP0699237B1 (en) * 1994-03-17 2003-02-19 MERCK PATENT GmbH Anti-egfr single-chain fvs and anti-egfr antibodies
WO2005056606A2 (en) * 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
WO2006082515A2 (en) * 2005-02-07 2006-08-10 Glycart Biotechnology Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
US7220750B2 (en) 1999-06-21 2007-05-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US7247301B2 (en) 2001-06-13 2007-07-24 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
WO2008017963A2 (en) 2006-08-09 2008-02-14 Glycart Biotechnology Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
EP2042517A1 (en) 2002-09-27 2009-04-01 Xencor, Inc. Optimized FC variants and methods for their generation
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2116245A2 (en) 2004-08-07 2009-11-11 Boehringer Ingelheim International GmbH EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
US7625558B2 (en) 1998-03-04 2009-12-01 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
EP2221315A1 (en) 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
EP2325206A2 (en) 2004-11-12 2011-05-25 Xencor, Inc. FC variants with altered binding to FCRN
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
EP2368911A1 (en) 2003-05-02 2011-09-28 Xencor Inc. Optimized Fc variants and methods for their generation
EP2384751A1 (en) 2004-12-24 2011-11-09 Boehringer Ingelheim International Gmbh Medicaments for the treatment or prevention of fibrotic diseases
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
WO2012016227A2 (en) 2010-07-29 2012-02-02 Xencor, Inc. Antibodies with modified isoelectric points
EP2444423A1 (en) 2007-10-31 2012-04-25 Xencor Inc. Fc variants with altered binding to FcRn
EP2471813A1 (en) 2004-07-15 2012-07-04 Xencor Inc. Optimized Fc variants
EP2495257A2 (en) 2005-08-19 2012-09-05 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2012121775A2 (en) 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
EP2500356A2 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2013009868A1 (en) 2011-07-11 2013-01-17 Yale University Compositions and methods for making selenocysteine containing polypeptides
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
US8414896B2 (en) 2007-03-01 2013-04-09 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
WO2013055809A1 (en) 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
US8426586B2 (en) 2003-10-17 2013-04-23 Boehringer Ingelheim International Gmbh Process for preparing amino crotonyl compounds
WO2013063095A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
US8586714B2 (en) 2009-09-01 2013-11-19 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
WO2013185115A1 (en) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US8663640B2 (en) 2008-08-29 2014-03-04 Symphogen A/S Methods using recombinant anti-epidermal growth factor receptor antibody compositions
US8664367B2 (en) 2010-05-14 2014-03-04 Abbvie, Inc. IL-I binding proteins
WO2014036492A1 (en) 2012-08-31 2014-03-06 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
US8716450B2 (en) 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2014071212A2 (en) 2012-11-01 2014-05-08 Abbvie Inc. Stable dual variable domain immunoglobulin protein formulations
US8722855B2 (en) 2009-10-28 2014-05-13 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
EP2772269A2 (en) 2009-03-05 2014-09-03 Abbvie Inc. IL-17 binding proteins
WO2014144960A2 (en) 2013-03-15 2014-09-18 Abbvie Biotherapeutics Inc. Fc variants
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
US8877764B2 (en) 2006-09-18 2014-11-04 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
EP2808343A1 (en) 2007-12-26 2014-12-03 Xencor Inc. Fc variants with altered binding to FcRn
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US8937158B2 (en) 2003-03-03 2015-01-20 Xencor, Inc. Fc variants with increased affinity for FcγRIIc
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
WO2015038984A2 (en) 2013-09-12 2015-03-19 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
US8987418B2 (en) 2013-03-15 2015-03-24 Abbvie Inc. Dual specific binding proteins directed against IL-1β and/or IL-17
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015057906A1 (en) * 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9035027B2 (en) 2008-06-03 2015-05-19 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9040041B2 (en) 2005-10-03 2015-05-26 Xencor, Inc. Modified FC molecules
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9045551B2 (en) 2012-11-01 2015-06-02 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
US9072798B2 (en) 2009-02-18 2015-07-07 Ludwig Institute For Cancer Research Ltd. Specific binding proteins and uses thereof
US9089571B2 (en) 2005-11-11 2015-07-28 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
EP2921177A2 (en) 2010-07-09 2015-09-23 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2016062851A1 (en) 2014-10-23 2016-04-28 Innate Pharma Treatment of cancers using anti-nkg2a agents
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US9562102B2 (en) 2001-05-11 2017-02-07 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US9650446B2 (en) 2013-01-14 2017-05-16 Xencor, Inc. Heterodimeric proteins
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP3208281A1 (en) 2010-03-29 2017-08-23 Zymeworks, Inc. Antibodies with enhanced or suppressed effector function
WO2017158426A1 (en) 2016-03-14 2017-09-21 University Of Oslo Engineered immunoglobulins with altered fcrn binding
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US9822186B2 (en) 2014-03-28 2017-11-21 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
US9840554B2 (en) 2015-06-15 2017-12-12 Abbvie Inc. Antibodies against platelet-derived growth factor (PDGF)
WO2017218698A1 (en) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
US9850320B2 (en) 2014-11-26 2017-12-26 Xencor, Inc. Heterodimeric antibodies to CD3 X CD20
US9856327B2 (en) 2014-11-26 2018-01-02 Xencor, Inc. Heterodimeric antibodies to CD3 X CD123
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
EP3424530A1 (en) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
WO2019071023A1 (en) 2017-10-04 2019-04-11 Yale University Compositions and methods for making selenocysteine containing polypeptides
US10280227B2 (en) 2009-09-11 2019-05-07 Genentech, Inc. Highly concentrated pharmaceutical formulations
US10316088B2 (en) 2016-06-28 2019-06-11 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
EP3524620A1 (en) 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10501543B2 (en) 2016-10-14 2019-12-10 Xencor, Inc. IL15/IL15Rα heterodimeric Fc-fusion proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10526417B2 (en) 2014-11-26 2020-01-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
WO2020028909A1 (en) 2018-08-03 2020-02-06 Brown University Oral formulations with increased uptake
WO2020076849A1 (en) 2018-10-11 2020-04-16 The Scripps Research Institute Antibody compounds with reactive arginine and related antibody drug conjugates
WO2020136147A1 (en) 2018-12-26 2020-07-02 Innate Pharma Compounds and methods for treatment of head and neck cancer
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
WO2020252043A1 (en) 2019-06-10 2020-12-17 Sutro Biopharma, Inc. 5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF
WO2020257235A1 (en) 2019-06-17 2020-12-24 Sutro Biopharma, Inc. 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2021118924A2 (en) 2019-12-12 2021-06-17 Ting Therapeutics Llc Compositions and methods for the prevention and treatment of hearing loss
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
WO2022074206A1 (en) 2020-10-08 2022-04-14 Affimed Gmbh Trispecific binders
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
WO2022103983A2 (en) 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
US11358999B2 (en) 2018-10-03 2022-06-14 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
US11472890B2 (en) 2019-03-01 2022-10-18 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
WO2023007023A1 (en) 2021-07-30 2023-02-02 Affimed Gmbh Duplexbodies
US11591401B2 (en) 2020-08-19 2023-02-28 Xencor, Inc. Anti-CD28 compositions
WO2023078968A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
WO2023164487A1 (en) 2022-02-22 2023-08-31 Brown University Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
WO2024006272A1 (en) 2022-06-27 2024-01-04 Sutro Biopharma, Inc. β-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF
WO2024015229A1 (en) 2022-07-15 2024-01-18 Sutro Biopharma, Inc. Protease/enzyme cleavable linker-payloads and protein conjugates
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US11987615B2 (en) 2020-04-26 2024-05-21 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Modified immunoglobulins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
WO1992015683A1 (en) * 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
WO1992015683A1 (en) * 1991-03-06 1992-09-17 MERCK Patent Gesellschaft mit beschränkter Haftung Humanized and chimeric monoclonal antibodies

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
C. DEAN ET AL.: "Immunotherapy with antibodies to the EGF receptor.", INTERNATIONAL JOURNAL OF CANCER, vol. 57, no. SUP8, 1994, GENEVA, SWITZERLAND, pages 103 - 107 *
H. MODJTAHEDI ET AL.: "Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGF receptor.", CELL BIOPHYSICS, vol. 22, no. 1-3, January 1993 (1993-01-01), CLIFTON NJ, USA, pages 129 - 146 *
H. MODJTAHEDI ET AL.: "Differentiation or immune destruction: Two pathways for therapy of sqamous cell carcinoma with antibodies to the epidermal growth factor receptor.", CANCER RESEARCH, vol. 54, no. 7, 1 April 1994 (1994-04-01), PHILADELPHIA PA, USA, pages 1695 - 1701 *
H. MODJTAHEDI ET AL.: "Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction.", BRITISH JOURNAL OF CANCER, vol. 67, no. 2, February 1993 (1993-02-01), LONDON, GB, pages 254 - 261 *
H. MODJTAHEDI ET AL.: "The growth response of human tumour cell lines expressing the EGF receptor to treatment with EGF and/or Mabs that block ligand binding.", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 3, no. 2, August 1993 (1993-08-01), ATHENS, GREECE, pages 237 - 243 *
H. MODJTAHEDI ET AL.: "The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468.", BRITISH JOURNAL OF CANCER, vol. 67, no. 2, February 1993 (1993-02-01), LONDON, GB, pages 247 - 253 *
K. CARRAWAY ET AL.: "Inhibition of epidermal growth factor receptor aggregation by an antibody directed against the epidermal growth factor receptor extracellular domain.", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 32, 15 November 1993 (1993-11-15), BALTIMORE MD, USA, pages 23860 - 23867 *
Z. FAN ET AL.: "Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.", CANCER RESEARCH, vol. 53, no. 18, 15 September 1993 (1993-09-15), PHILADELPHIA PA, USA, pages 4322 - 4328 *

Cited By (253)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0699237B1 (en) * 1994-03-17 2003-02-19 MERCK PATENT GmbH Anti-egfr single-chain fvs and anti-egfr antibodies
EP0712863B1 (en) * 1994-11-18 2002-02-27 Centro de Inmunologia Molecular Humanized and chimeric monoclonal antibodies that recognize epidermal growth factor receptor (EGF-R); diagnostic and therapeutic use
US7625558B2 (en) 1998-03-04 2009-12-01 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US7220750B2 (en) 1999-06-21 2007-05-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US8722694B2 (en) 1999-06-21 2014-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US7776315B2 (en) 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
USRE43431E1 (en) 2000-12-20 2012-05-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US8586608B2 (en) 2000-12-20 2013-11-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US9562102B2 (en) 2001-05-11 2017-02-07 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
US9458236B2 (en) 2001-06-13 2016-10-04 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7247301B2 (en) 2001-06-13 2007-07-24 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US8586041B2 (en) 2001-06-13 2013-11-19 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP2298805A2 (en) 2002-09-27 2011-03-23 Xencor, Inc. Optimized Fc variants and methods for their generation
EP2364996A1 (en) 2002-09-27 2011-09-14 Xencor Inc. Optimized FC variants and methods for their generation
EP3321282A1 (en) 2002-09-27 2018-05-16 Xencor, Inc. Optimized fc variants and methods for their generation
EP3150630A1 (en) 2002-09-27 2017-04-05 Xencor Inc. Optimized fc variants and methods for their generation
EP2042517A1 (en) 2002-09-27 2009-04-01 Xencor, Inc. Optimized FC variants and methods for their generation
EP3502133A1 (en) 2002-09-27 2019-06-26 Xencor, Inc. Optimized fc variants and methods for their generation
EP2345671A1 (en) 2002-09-27 2011-07-20 Xencor Inc. Optimized fc variants and methods for their generation
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
US8937158B2 (en) 2003-03-03 2015-01-20 Xencor, Inc. Fc variants with increased affinity for FcγRIIc
EP3838920A1 (en) 2003-05-02 2021-06-23 Xencor, Inc. Optimized fc variants and methods for their generation
EP3101030A1 (en) 2003-05-02 2016-12-07 Xencor, Inc. Optimized fc variants and methods for their generation
EP2368911A1 (en) 2003-05-02 2011-09-28 Xencor Inc. Optimized Fc variants and methods for their generation
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US8426586B2 (en) 2003-10-17 2013-04-23 Boehringer Ingelheim International Gmbh Process for preparing amino crotonyl compounds
WO2005056606A2 (en) * 2003-12-03 2005-06-23 Xencor, Inc Optimized antibodies that target the epidermal growth factor receptor
WO2005056606A3 (en) * 2003-12-03 2005-09-09 Xencor Inc Optimized antibodies that target the epidermal growth factor receptor
EP2221315A1 (en) 2003-12-04 2010-08-25 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
EP3342782A1 (en) 2004-07-15 2018-07-04 Xencor, Inc. Optimized fc variants
EP2471813A1 (en) 2004-07-15 2012-07-04 Xencor Inc. Optimized Fc variants
EP2116245A2 (en) 2004-08-07 2009-11-11 Boehringer Ingelheim International GmbH EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
US11198739B2 (en) 2004-11-12 2021-12-14 Xencor, Inc. Fc variants with altered binding to FcRn
US10336818B2 (en) 2004-11-12 2019-07-02 Xencor, Inc. Fc variants with altered binding to FcRn
US9803023B2 (en) 2004-11-12 2017-10-31 Xencor, Inc. Fc variants with altered binding to FcRn
US8883973B2 (en) 2004-11-12 2014-11-11 Xencor, Inc. Fc variants with altered binding to FcRn
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
EP2325206A2 (en) 2004-11-12 2011-05-25 Xencor, Inc. FC variants with altered binding to FCRN
EP2845865A1 (en) 2004-11-12 2015-03-11 Xencor Inc. Fc variants with altered binding to FcRn
US8852586B2 (en) 2004-11-12 2014-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
EP2332985A2 (en) 2004-11-12 2011-06-15 Xencor, Inc. Fc variants with altered binding to FcRn
EP2878297A1 (en) 2004-12-24 2015-06-03 Boehringer Ingelheim International GmbH Medicaments for the treatment or prevention of fibrotic diseases
EP2384751A1 (en) 2004-12-24 2011-11-09 Boehringer Ingelheim International Gmbh Medicaments for the treatment or prevention of fibrotic diseases
US7722867B2 (en) 2005-02-07 2010-05-25 Glycart Biotechnology Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
US8614065B2 (en) 2005-02-07 2013-12-24 Roche Glycart Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
WO2006082515A2 (en) * 2005-02-07 2006-08-10 Glycart Biotechnology Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
WO2006082515A3 (en) * 2005-02-07 2007-06-14 Glycart Biotechnology Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
EP3660049A1 (en) 2005-02-07 2020-06-03 Roche Glycart AG Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
US7846432B2 (en) 2005-02-07 2010-12-07 Glycart Biotechnology Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
CN101115773B (en) * 2005-02-07 2015-06-10 罗氏格黎卡特股份公司 Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
EP2402374A1 (en) 2005-02-07 2012-01-04 GlycArt Biotechnology AG Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
RU2610688C2 (en) * 2005-02-07 2017-02-14 Роше Гликарт Аг Antigen-binding molecules, which bind egfr, vectors coding them and use thereof
EP2404937A1 (en) 2005-02-07 2012-01-11 GlycArt Biotechnology AG Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
US8097436B2 (en) 2005-02-07 2012-01-17 Roche Glycart Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
US9309317B2 (en) 2005-02-07 2016-04-12 Roche Glycart Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
AU2006211037B2 (en) * 2005-02-07 2012-05-24 Roche Glycart Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
US9957326B2 (en) 2005-02-07 2018-05-01 Roche Glycart Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
EP2495257A2 (en) 2005-08-19 2012-09-05 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500356A2 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500355A2 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2520588A1 (en) 2005-08-19 2012-11-07 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500357A2 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500354A2 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500359A2 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500352A1 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500353A2 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2500358A2 (en) 2005-08-19 2012-09-19 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US9040041B2 (en) 2005-10-03 2015-05-26 Xencor, Inc. Modified FC molecules
US9539258B2 (en) 2005-11-11 2017-01-10 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US9089571B2 (en) 2005-11-11 2015-07-28 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US7662377B2 (en) 2006-08-09 2010-02-16 Glycart Biotechnology Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
US8273328B2 (en) 2006-08-09 2012-09-25 Roche Glycart Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
US7727741B2 (en) 2006-08-09 2010-06-01 Glycart Biotechnology Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
WO2008017963A2 (en) 2006-08-09 2008-02-14 Glycart Biotechnology Ag Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
US9074008B2 (en) 2006-08-09 2015-07-07 Roche Glycart Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
US8088380B2 (en) 2006-08-09 2012-01-03 Roche Glycart Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
EP2444422A2 (en) 2006-08-09 2012-04-25 GlycArt Biotechnology AG Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
US8877764B2 (en) 2006-09-18 2014-11-04 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
US8414896B2 (en) 2007-03-01 2013-04-09 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
EP2444423A1 (en) 2007-10-31 2012-04-25 Xencor Inc. Fc variants with altered binding to FcRn
EP3138853A1 (en) 2007-10-31 2017-03-08 Xencor, Inc. Fc variants with altered binding to fcrn
US11932685B2 (en) 2007-10-31 2024-03-19 Xencor, Inc. Fc variants with altered binding to FcRn
EP2937361A2 (en) 2007-10-31 2015-10-28 Xencor Inc. Fc variants with altered binding to fcRn
EP3825329A1 (en) 2007-12-26 2021-05-26 Xencor, Inc. Fc variants with altered binding to fcrn
EP3575317A1 (en) 2007-12-26 2019-12-04 Xencor, Inc. Fc variants with altered binding to fcrn
EP2808343A1 (en) 2007-12-26 2014-12-03 Xencor Inc. Fc variants with altered binding to FcRn
EP4269443A2 (en) 2007-12-26 2023-11-01 Xencor, Inc. Fc variants with altered binding to fcrn
EP4098661A1 (en) 2007-12-26 2022-12-07 Xencor, Inc. Fc variants with altered binding to fcrn
US9029508B2 (en) 2008-04-29 2015-05-12 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP2899209A1 (en) 2008-04-29 2015-07-29 Abbvie Inc. Dual Variable Domain Immunoglobulins and uses thereof
EP3002299A1 (en) 2008-06-03 2016-04-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
US9035027B2 (en) 2008-06-03 2015-05-19 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9109026B2 (en) 2008-06-03 2015-08-18 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
US8822645B2 (en) 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US8663640B2 (en) 2008-08-29 2014-03-04 Symphogen A/S Methods using recombinant anti-epidermal growth factor receptor antibody compositions
EP3524620A1 (en) 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
US9072798B2 (en) 2009-02-18 2015-07-07 Ludwig Institute For Cancer Research Ltd. Specific binding proteins and uses thereof
EP2810652A2 (en) 2009-03-05 2014-12-10 AbbVie Inc. IL-17 binding proteins
US9481736B2 (en) 2009-03-05 2016-11-01 Abbvie, Inc. IL-17 binding proteins
US9663587B2 (en) 2009-03-05 2017-05-30 Abbvie Inc. IL-17 binding proteins
EP2772269A2 (en) 2009-03-05 2014-09-03 Abbvie Inc. IL-17 binding proteins
US9481735B2 (en) 2009-03-05 2016-11-01 Abbvie Inc. IL-17 binding proteins
US8835610B2 (en) 2009-03-05 2014-09-16 Abbvie Inc. IL-17 binding proteins
US9545381B2 (en) 2009-07-06 2017-01-17 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US10004743B2 (en) 2009-07-06 2018-06-26 Boehringer Ingelheim International Gmbh Process for drying of BIBW2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US8586714B2 (en) 2009-09-01 2013-11-19 Abbvie, Inc. Dual variable domain immunoglobulins and uses thereof
US11401348B2 (en) 2009-09-02 2022-08-02 Xencor, Inc. Heterodimeric Fc variants
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US10752696B2 (en) 2009-09-11 2020-08-25 Genentech, Inc. Highly concentrated pharmaceutical formulations
US10377831B2 (en) 2009-09-11 2019-08-13 Genentech, Inc. Highly concentrated pharmaceutical formulations
US10280227B2 (en) 2009-09-11 2019-05-07 Genentech, Inc. Highly concentrated pharmaceutical formulations
US8716450B2 (en) 2009-10-15 2014-05-06 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US8722855B2 (en) 2009-10-28 2014-05-13 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
EP3208281A1 (en) 2010-03-29 2017-08-23 Zymeworks, Inc. Antibodies with enhanced or suppressed effector function
US9447184B2 (en) 2010-05-14 2016-09-20 Abbvie Inc. IL-1 binding proteins
US9447183B2 (en) 2010-05-14 2016-09-20 Abbvie Inc. IL-1 binding proteins
US9441038B2 (en) 2010-05-14 2016-09-13 Abbvie Inc. IL-1 binding proteins
US9409986B2 (en) 2010-05-14 2016-08-09 Abbvie Inc. IL-1 binding proteins
US8841417B2 (en) 2010-05-14 2014-09-23 Abbvie Inc. IL-1 binding proteins
US9303085B2 (en) 2010-05-14 2016-04-05 Abbvie Inc. IL-1 binding proteins
US8664367B2 (en) 2010-05-14 2014-03-04 Abbvie, Inc. IL-I binding proteins
WO2012006500A2 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
EP2921177A2 (en) 2010-07-09 2015-09-23 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
US9605061B2 (en) 2010-07-29 2017-03-28 Xencor, Inc. Antibodies with modified isoelectric points
EP3029066A2 (en) 2010-07-29 2016-06-08 Xencor, Inc. Antibodies with modified isoelectric points
WO2012016227A2 (en) 2010-07-29 2012-02-02 Xencor, Inc. Antibodies with modified isoelectric points
US9493560B2 (en) 2010-08-03 2016-11-15 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP3252072A2 (en) 2010-08-03 2017-12-06 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
US8735546B2 (en) 2010-08-03 2014-05-27 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012121775A2 (en) 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
WO2013009868A1 (en) 2011-07-11 2013-01-17 Yale University Compositions and methods for making selenocysteine containing polypeptides
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013055809A1 (en) 2011-10-10 2013-04-18 Xencor, Inc. A method for purifying antibodies
EP3611187A1 (en) 2011-10-10 2020-02-19 Xencor, Inc. A method for purifying antibodies
WO2013063095A1 (en) 2011-10-24 2013-05-02 Abbvie Inc. Immunobinders directed against sclerostin
US9120870B2 (en) 2011-12-30 2015-09-01 Abbvie Inc. Dual specific binding proteins directed against IL-13 and IL-17
EP3505534A1 (en) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
WO2013185115A1 (en) 2012-06-08 2013-12-12 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
US9670276B2 (en) 2012-07-12 2017-06-06 Abbvie Inc. IL-1 binding proteins
WO2014036492A1 (en) 2012-08-31 2014-03-06 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
EP4074728A1 (en) 2012-08-31 2022-10-19 Sutro Biopharma, Inc. Modified peptides comprising an azido group
EP3584255A1 (en) 2012-08-31 2019-12-25 Sutro Biopharma, Inc. Modified amino acids comprising an azido group
US9045551B2 (en) 2012-11-01 2015-06-02 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
US9944720B2 (en) 2012-11-01 2018-04-17 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
US9163093B2 (en) 2012-11-01 2015-10-20 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
EP3466973A1 (en) 2012-11-01 2019-04-10 AbbVie Inc. Stable dual variable domain immunoglobulin protein formulations
WO2014071212A2 (en) 2012-11-01 2014-05-08 Abbvie Inc. Stable dual variable domain immunoglobulin protein formulations
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10738133B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
US10738132B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
US9650446B2 (en) 2013-01-14 2017-05-16 Xencor, Inc. Heterodimeric proteins
US11634506B2 (en) 2013-01-14 2023-04-25 Xencor, Inc. Heterodimeric proteins
US11718667B2 (en) 2013-01-14 2023-08-08 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10472427B2 (en) 2013-01-14 2019-11-12 Xencor, Inc. Heterodimeric proteins
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11814423B2 (en) 2013-03-15 2023-11-14 Xencor, Inc. Heterodimeric proteins
US11299554B2 (en) 2013-03-15 2022-04-12 Xencor, Inc. Heterodimeric proteins
US8987418B2 (en) 2013-03-15 2015-03-24 Abbvie Inc. Dual specific binding proteins directed against IL-1β and/or IL-17
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
WO2014144960A2 (en) 2013-03-15 2014-09-18 Abbvie Biotherapeutics Inc. Fc variants
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10287364B2 (en) 2013-03-15 2019-05-14 Xencor, Inc. Heterodimeric proteins
EP3424530A1 (en) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3336103A1 (en) 2013-07-10 2018-06-20 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
WO2015038984A2 (en) 2013-09-12 2015-03-19 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015057906A1 (en) * 2013-10-16 2015-04-23 Janssen Biotech, Inc. Cd200 receptor 1 agonists
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
US10858451B2 (en) 2014-03-28 2020-12-08 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
US9822186B2 (en) 2014-03-28 2017-11-21 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
US11840579B2 (en) 2014-03-28 2023-12-12 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
EP3659625A1 (en) 2014-10-23 2020-06-03 Innate Pharma Treatment of cancers using anti-nkg2a agents
WO2016062851A1 (en) 2014-10-23 2016-04-28 Innate Pharma Treatment of cancers using anti-nkg2a agents
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US9856327B2 (en) 2014-11-26 2018-01-02 Xencor, Inc. Heterodimeric antibodies to CD3 X CD123
US12129309B2 (en) 2014-11-26 2024-10-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US11945880B2 (en) 2014-11-26 2024-04-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US11859011B2 (en) 2014-11-26 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US9850320B2 (en) 2014-11-26 2017-12-26 Xencor, Inc. Heterodimeric antibodies to CD3 X CD20
US11673972B2 (en) 2014-11-26 2023-06-13 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US11111315B2 (en) 2014-11-26 2021-09-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10889653B2 (en) 2014-11-26 2021-01-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10913803B2 (en) 2014-11-26 2021-02-09 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10526417B2 (en) 2014-11-26 2020-01-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US11352442B2 (en) 2014-11-26 2022-06-07 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
US11225528B2 (en) 2014-11-26 2022-01-18 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US11091548B2 (en) 2015-03-05 2021-08-17 Xencor, Inc. Modulation of T cells with bispecific antibodies and Fc fusions
US9840554B2 (en) 2015-06-15 2017-12-12 Abbvie Inc. Antibodies against platelet-derived growth factor (PDGF)
US11623957B2 (en) 2015-12-07 2023-04-11 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
WO2017158426A1 (en) 2016-03-14 2017-09-21 University Of Oslo Engineered immunoglobulins with altered fcrn binding
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US11236170B2 (en) 2016-06-14 2022-02-01 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US11492407B2 (en) 2016-06-14 2022-11-08 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
WO2017218698A1 (en) 2016-06-15 2017-12-21 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
US11225521B2 (en) 2016-06-28 2022-01-18 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10316088B2 (en) 2016-06-28 2019-06-11 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US12054545B2 (en) 2016-06-28 2024-08-06 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US10501543B2 (en) 2016-10-14 2019-12-10 Xencor, Inc. IL15/IL15Rα heterodimeric Fc-fusion proteins
US10550185B2 (en) 2016-10-14 2020-02-04 Xencor, Inc. Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments
US11084863B2 (en) 2017-06-30 2021-08-10 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains
WO2019071023A1 (en) 2017-10-04 2019-04-11 Yale University Compositions and methods for making selenocysteine containing polypeptides
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
WO2020028909A1 (en) 2018-08-03 2020-02-06 Brown University Oral formulations with increased uptake
US11358999B2 (en) 2018-10-03 2022-06-14 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
WO2020076849A1 (en) 2018-10-11 2020-04-16 The Scripps Research Institute Antibody compounds with reactive arginine and related antibody drug conjugates
WO2020136147A1 (en) 2018-12-26 2020-07-02 Innate Pharma Compounds and methods for treatment of head and neck cancer
US11472890B2 (en) 2019-03-01 2022-10-18 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
WO2020252043A1 (en) 2019-06-10 2020-12-17 Sutro Biopharma, Inc. 5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF
WO2020257235A1 (en) 2019-06-17 2020-12-24 Sutro Biopharma, Inc. 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
WO2021118924A2 (en) 2019-12-12 2021-06-17 Ting Therapeutics Llc Compositions and methods for the prevention and treatment of hearing loss
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
US11987615B2 (en) 2020-04-26 2024-05-21 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Modified immunoglobulins
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
US11591401B2 (en) 2020-08-19 2023-02-28 Xencor, Inc. Anti-CD28 compositions
WO2022074206A1 (en) 2020-10-08 2022-04-14 Affimed Gmbh Trispecific binders
WO2022103983A2 (en) 2020-11-11 2022-05-19 Sutro Biopharma, Inc. Fluorenylmethyloxycarbonyl and fluorenylmethylaminocarbonyl compounds, protein conjugates thereof, and methods for their use
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
US11859012B2 (en) 2021-03-10 2024-01-02 Xencor, Inc. Heterodimeric antibodies that bind CD3 and GPC3
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
WO2023007023A1 (en) 2021-07-30 2023-02-02 Affimed Gmbh Duplexbodies
WO2023078968A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
WO2023164487A1 (en) 2022-02-22 2023-08-31 Brown University Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
WO2024006272A1 (en) 2022-06-27 2024-01-04 Sutro Biopharma, Inc. β-GLUCURONIDE LINKER-PAYLOADS, PROTEIN CONJUGATES THEREOF, AND METHODS THEREOF
WO2024015229A1 (en) 2022-07-15 2024-01-18 Sutro Biopharma, Inc. Protease/enzyme cleavable linker-payloads and protein conjugates

Also Published As

Publication number Publication date
JPH09510605A (en) 1997-10-28
AU1460195A (en) 1995-08-08
EP0737251A1 (en) 1996-10-16
GB9401182D0 (en) 1994-03-16
AU691865B2 (en) 1998-05-28
CA2180834A1 (en) 1995-07-27

Similar Documents

Publication Publication Date Title
AU691865B2 (en) Antibodies to egf receptor and their antitumour effect
CA2107553C (en) Monoclonal antibodies to stem cell factor receptors
Modjtahedi et al. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer
Naramura et al. Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma
Kurpad et al. Tumor antigens in astrocytic gliomas
Borsi et al. Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin
KR100269879B1 (en) A combination of anti-erbb-2 monoclonal antibodies and method of using.
DE69630313T2 (en) APOPTOSIS INDUCED WITH ANTI-HER2 MONOCLONAL ANTIBODY
US5677171A (en) Monoclonal antibodies directed to the HER2 receptor
DE69605181T2 (en) ANTIBODIES AGAINST CD30, PREVENT PROTEOLYTIC CLEAVAGE AND DISTRIBUTION OF MEMBRANE-BINDING CD30
Chandramohan et al. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy
CA2073124C (en) Tumor antigen specific antibody
CA2447139A1 (en) Specific binding proteins and uses thereof
CZ295531B6 (en) Isolated antibody, process for its preparation and use
US6024955A (en) Peptides and monoclonal antibodies
JPH08511940A (en) Monoclonal antibody against αPDGF receptor and use thereof
JP2001521520A (en) Anti-α-low v ▼ β-low 3 ▼ Integrin antibody antagonist
Sharifi et al. Characterization of a phage display-derived human monoclonal antibody (NHS76) counterpart to chimeric TNT-1 directed against necrotic regions of solid tumors
Dorvillius et al. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen
Reist et al. In vitro and in vivo behavior of radiolabeled chimeric anti-EGFRvIII monoclonal antibody: comparison with its murine parent
AU616161B2 (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
Pietersz et al. Comparison of the biological properties of two anti-mucin-1 antibodies prepared for imaging and therapy
JP2003517482A (en) Diagnostic and therapeutic methods by binding of p75 / AIRM1
Oldham et al. Individually specified drug immunoconjugates in cancer treatment
Ditzel et al. Immunoscintigraphy of colon cancers with the human monoclonal antibody cou‐1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2180834

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 278630

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1995906400

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1996 669424

Country of ref document: US

Date of ref document: 19960930

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1995906400

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1995906400

Country of ref document: EP